Research and investment in the science of Longevity has exploded over the last 10 years and continues to grow at pace. Following the lead of Dr David Sinclair, many research scientists are now proactively sharing the work that they are doing with us, the Longevity community.
What are Biogerontologists
Biogerontology is a field of gerontology which is concerned with the biological aging process, and potential ways to intervene and reverse in the process. Many of the Longevity scientists below are in the field of biogerontology and are moving the dial on how we understand the aging process.
Who are the top scientists in Longevity
We've compiled a list of the top longevity scientists in the UK and across the world so that you can stay informed with the cutting edge science that is being developed that will help us all live long and healthy lives.
David Andrew Sinclair AO (born June 26, 1969) is an Australian biologist who is a professor of genetics and co-director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. He is known for his research on aging with a focus on epigenetics. He is an officer of the Order of Australia (AO).
Sinclair has appeared in Time magazine, The New York Times, The Charlie Rose Show, 60 Minutes, Boston magazine, The Washington Post, The Economist, TED and The Joe Rogan Experience.
Title: Professor of genetics
Roles: Co-director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School"
Specialism: He is known for his research on aging with a focus on epigenetics Molecular Genetics
Aubrey de Grey
Aubrey David Nicholas Jasper de Grey; born 20 April 1963 is an English author and biomedical gerontologist. He is the author of The Mitochondrial Free Radical Theory of Aging (1999) and co-author of Ending Aging (2007). He is known for his view that medical technology may enable human beings alive today not to die from age-related causes. As an amateur mathematician, he has contributed to the study of the Hadwiger–Nelson problem in geometric graph theory, making the first progress on the problem in over 60 years.
De Grey is an international adjunct professor of the Moscow Institute of Physics and Technology, a fellow of the Gerontological Society of America, the American Aging Association, and the Institute for Ethics and Emerging Technologies. He has been interviewed in recent years in a number of news sources, including CBS 60 Minutes, the BBC, The Guardian, Fortune Magazine, The Washington Post, TED, Popular Science, The Colbert Report, Time, the Skeptics' Guide to the Universe, and The Joe Rogan Experience. He was the Chief Science Officer of the SENS Research Foundation, but was fired in August 2021 after allegedly interfering in a probe investigating sexual harassment allegations against him.
Title: English author and biomedical gerontologist
Roles: known for his view that medical technology may enable human beings alive today not to die from age-related causes
Valter D. Longo (born October 9, 1967) is an Italian-American biogerontologist and cell biologist known for his studies on the role of fasting and nutrient response genes on cellular protection aging and diseases and for proposing that longevity is regulated by similar genes and mechanisms in many eukaryotes. He is currently a professor at the USC Davis School of Gerontology with a joint appointment in the department of Biological Sciences as well as serving as the director of the USC Longevity Institute.
Title: Professor of Gerontology and Biological Sciences at Edna M. Jones and Director of the Longevity Institute at the University of Southern California –Leonard Davis School of Gerontology, Los Angeles
Roles: known for his studies on the role of fasting and nutrient response genes on cellular protection aging and diseases and for proposing that longevity is regulated by similar genes and mechanisms in many eukaryotes
Specialism: Biogerontology & Cell Biology
S. Jay Olshansky
Stuart Jay Olshansky (born February 22, 1954) is a professor in the School of Public Health at the University of Illinois at Chicago concentrating on biodemography and gerontology and is co-founder and Chief Scientist at Lapetus Solutions, Inc.
He is also a research associate at the Center on Aging (University of Chicago) and at the London School of Hygiene and Tropical Medicine. Olshansky is an associate editor of the Journal of Gerontology: Biological Sciences and Biogerontology and is a member of the editorial boards of several other scientific journals. Olshansky has been working with colleagues in the biological sciences to develop the modern "biodemographic paradigm" of mortality – an effort to understand the biological nature of the survival and dying out processes of living organisms. The focus of his research has been on estimates of the upper limits to human longevity, exploring the health and public policy implications associated with individual and population aging, forecasts of the size, survival, and age structure of the population, pursuit of the scientific means to slow aging in people (The Longevity Dividend), and global implications of the re-emergence of infectious and parasitic diseases, and insurance linked securities.
Title: Professor of Epidemiology and Biostatistics at the University of Illinois at Chicago School of Public Health and Co-founder and Chief Scientist at Lapetus Solutions, Inc
Specialism: Biodemography and Gerontology
Suresh Rattan (full name: Suresh Inder Singh Rattan; born in 1955 in Amritsar, India) is a biogerontologist – a researcher in the field of biology of ageing, biogerontology.
In addition to his professional research work on the biology of ageing, he is also very much interested and involved in the public communication of science and he likes to undertake explorations in the Indian classical music and semi-classical music by playing Tabla – the North Indian drums, as evident from music CDs "State of the Art: Small Town People" by Harry Jokumsen and other artists (2008), and "The Fall and the Rise of a Woman" by Pearl (2014) in which he plays Tabla under his artistic name Shashi Maharaj
Title: Biogerontologist at the Aarhus University's Department of Molecular Biology and Genetics
João Pedro de Magalhães
João Pedro de Magalhães is a Portuguese microbiologist at the University of Liverpool. His lab at the University of Liverpool studies aging through both computational and experimental approaches. His ultimate goal is to cure human aging.
In 1999, he obtained his degree in Microbiology from Escola Superior de Biotecnologia. Under Olivier Toussaint, he obtained his PhD from the University of Namur in 2004. Then he did a postdoc in the George Church lab from 2004 to 2008.
He helps maintain several databases on aging - among them - GenAge, AnAge, DrugAge, CellAge, GenDR, the Digital Aging Atlas, and Who's Who in Gerontology. His research group helped sequence the transcriptome of the long-lived bowhead whale. He also helps advise the Lifeboat Foundation.
Among his many longevity-related scientific research projects, Magalhães has sequenced and analyzed the genome of the bowhead whale. And he has also contributed to analysis of the genome of the naked mole rat. Both of these mammals are exceptionally long-lived and exceptionally cancer-resistant.
Title: Professor at the University of Birmingham
Dr. Matt Kaeberlein is a Professor of Laboratory Medicine and Pathology at the University of Washington School of Medicine. Dr. Kaeberlein’s research interests are focused on biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. He has published more than 200 scientific papers and has been recognized by several prestigious awards including young investigator awards from the Ellison Medical Foundation and the Alzheimer’s Association, the Vincent Cristofalo Rising Start in Aging Research Award, the Murdock Trust Award, the Kleemeier Award from the Gerontological Society of America (GSA), and the National Institute on Aging (NIA) Nathan W. Shock Award. Dr. Kaeberlein has been awarded Fellow status with the American Association for the Advancement of Science (AAAS), the American Aging Association (AGE), and GSA. He is currently the CEO and Chair of AGE and has served on the Board of Directors for the Federation of American Societies for Experimental Biology (FASEB) and AGE, and on Council for GSA. Dr. Kaeberlein is the founding Director of the University of Washington (UW) Healthy Aging and Longevity Research Institute, the Director of the NIH Nathan Shock Center of Excellence in the Basic Biology of Aging at UW, Director of the T32 Biological Mechanisms of Healthy Aging Training Program, and founder and co-Director of the Dog Aging Project.
Title : Professor of Laboratory Medicine and Pathology, University of Washington
Role/s: Dr. Kaeberlein’s research interests are focused on biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life.
Specialism: Biology and Biogerontology
Andrew George Dillin is a Howard Hughes Medical Investigator and the Thomas and Stacey Siebel Distinguished Chair in Stem Cell Research at the Department of Molecular and Cell Biology at Berkeley . His lab studies the loss of protein homeostasis in aging, particularly in Caenorhabditis elegans.
His lab specifically looks at the manipulation of stress response pathways, such as the heat shock response and the unfolded protein response of the mitochondria and the endoplasmic reticulum. In particular, his lab found a cell non-autonomous mitochondrial stress response that can be transmitted to very distal cells.
Title: Professor, Dept of Molecular & Cell Biology at Helen Wills Neuroscience Institute
Specialism: Endocrinology and Genetics of aging
The focus of her PhD studies was to gain a new focus on the core pluripotency factor NANOG, and extend its function to adult tissues and cancer. Experience with: Mouse models, human/mouse reprogramming, retrovirus/lentivirus transfection, primary culture/extraction of keratinocytes, mouse carcinogenesis assays, qRT-PCR, immunoblots, immunofluorescence, cloning, flow cytometry.
Title: Scientist I at Biogen
Specialism: Muscle stem cell biology, Muscle regeneration & Muscle biology
Ana Maria Cuervo
Dr. Cuervo is co-director of the Einstein Institute for Aging Research, and a member of the Einstein Liver Research Center and Cancer Center. In 2001 she started her laboratory at Einstein, where she studies the role of protein-degradation in aging and age-related disorders, with emphasis in neurodegeneration and metabolic disorders.
Dr. Cuervo’s group is interested in understanding how altered proteins can be eliminated from the cells and their components recycled. Her group has linked alterations in lysosomal protein degradation (autophagy) with different neurodegenerative diseases including Parkinson’s, Alzheimer’s and Huntington’s disease. They have also proven that restoration of normal lysosomal function prevents accumulation of damaged proteins with age, demonstrating this way that removal of these toxic products is possible. Her lab has also pioneered studies demonstrating a tight link between autophagy and cellular metabolism. They described how autophagy coordinates glucose and lipid metabolism and how failure of different autophagic pathways with age contribute to important metabolic disorders such as diabetes or obesity.
Title: Co-director of the Einstein Institute for Aging Research & Member of the Einstein Liver Research Center and Cancer Center
Specialism: Molecular Biology and Hepatology
Brunet's lab works on discovering lifespan-regulating genes and their interactions with the environment. Next, she studies how conserved 'pro-longevity genes' (e.g. FOXO transcription factors) regulate longevity in mammals, the regenerative potential of stem cells, and the nervous system. She uses mammalian tissue culture and C. elegans as model systems to study longevity pathways, dietary restriction, and epigenetic (chromatin-state) regulation of longevity by the environment. In addition, she is developing the extremely short-lived African killifish N. furzeri as a new vertebrate model for aging.
Dr. Brunet is interested in the molecular mechanisms of aging and longevity, with a particular emphasis on the nervous system. Her lab is interested in identifying pathways involved in delaying aging in response to external stimuli such as availability of nutrients and mates. She also seeks to understand the mechanisms that influence the rejuvenation of old stem cells. Finally, her lab has pioneered the naturally short-lived African killifish as a new model to explore the regulation of aging and age-related diseases.
Title: Professor at Stanford University
Specialism: Genetics & molecular mechanisms of aging and longevity, with a particular emphasis on the nervous system
Carol Greider, Ph.D. received her bachelor’s degree from the University of California at Santa Barbara in 1983 and a Ph.D. in 1987 from the University of California at Berkeley. In 1984, working together with Dr. Elizabeth Blackburn, she discovered telomerase, an enzyme that maintains telomeres, or chromosome ends. In 1988, Dr. Greider went to Cold Spring Harbor Laboratory where, as an independent Cold Spring Harbor Fellow, she cloned and characterized the RNA component of telomerase. In 1990, Dr. Greider was appointed as an assistant investigator at Cold Spring Harbor Laboratory, followed later by appointment to Investigator in 1994. She expanded the focus of her telomere research to include the role of telomere length in cellular senescence, cell death and in cancer.
In 1997, Dr. Greider moved her laboratory to the Department of Molecular Biology and Genetics at The Johns Hopkins University School of Medicine. In 2003 she was appointed as the Daniel Nathans Professor and Director of the Department of Molecular Biology and Genetics. At Johns Hopkins University, Dr. Greider’s group continued to study the biochemistry of telomerase and determined the secondary structure of the human telomerase RNA. In addition she characterized the loss of telomere function in mice, which allowed an understanding of humans short telomere diseases such as bone marrow and other stem cell failure diseases. Dr. Greider shared the Nobel Prize in Physiology or Medicine in 2009 with Drs. Elizabeth Blackburn and Jack Szostak for their work on telomeres and telomerase. Dr. Greider currently directs a group of eight scientists studying both the role of short telomeres in age-related disease and cancer as well as the regulatory mechanism that maintain telomere length.
Title: Distinguished Professor of Molecular, Cell & Developmental Biology UC Santa Cruz at University of California, Santa Cruz
Specialism: Molecular Biology, Genetics & Co-discovered "telomerase"
Cynthia Kenyon graduated valedictorian in chemistry and biochemistry from the University of Georgia in 1976. She received her PhD in 1981 from MIT where, in Graham Walker's laboratory, she looked for genes on the basis of their activity profiles, discovering that DNA-damaging agents activate a battery of DNA repair genes in E. coli. She then did postdoctoral studies with Nobel laureate Sydney Brenner at the MRC Laboratory of Molecular Biology in Cambridge, England, studying the development of C. elegans.
Since 1986 she has been at the University of California, San Francisco (UCSF), where she was the Herbert Boyer Distinguished Professor of Biochemistry and Biophysics and is now an American Cancer Society Professor. In 1999 she co-founded Elixir Pharmaceuticals with Leonard Guarente to try to discover and develop drugs that would slow down the process that makes people age. In April 2014, Kenyon was named Vice President of Aging Research at Calico, a new company focused on health, well-being, and longevity. Prior to that, she served as a part-time advisor beginning in November 2013. Kenyon will remain affiliated with UCSF as an emeritus professor.
Title: Director of the Hillblom Center for the Biology of Aging at UCSF
Specialism: Biochemistry & Biophysics
Elizabeth Helen Blackburn, AC FRS FAA FRSN (born 26 November 1948) is an Australian-American Nobel laureate who is the former President of the Salk Institute for Biological Studies. Previously she was a biological researcher at the University of California, San Francisco, who studied the telomere, a structure at the end of chromosomes that protects the chromosome. In 1984, Blackburn co-discovered telomerase, the enzyme that replenishes the telomere, with Carol W. Greider. For this work, she was awarded the 2009 Nobel Prize in Physiology or Medicine, sharing it with Greider and Jack W. Szostak, becoming the only Tasmanian-born Nobel laureate. She also worked in medical ethics, and was controversially dismissed from the Bush Administration's President's Council on Bioethics.
Title: Morris Herzstein Professor Emerita, Department of Biochemistry and Biophysics at UCSF
Janet Lord is director of the MRC-ARUK Centre for Musculoskeletal Ageing Research and the Institute of Inflammation and Ageing, both located within the new Queen Elizabeth super Hospital which opened in the summer of 2011.
Janet’s research focuses on the innate immune system, the body’s front line defense against infection, and how the efficiency of this system is affected by ageing and stress, the latter including physical trauma and emotional stress such as bereavement. She is also interested in how the ageing of the immune system predisposes adults to chronic inflammatory diseases such as Rheumatoid Arthritis and COPD and the muscle wasting associated with age and these conditions. In all of her work she aims to translate research findings into interventions, whether lifestyle (exercise, diet) or pharmacological, to improve immunity and health in old age.
Title: Director of the Institute of Inflammation and Ageing, University of Birmingham
Role/s: "I am currently director of the Centre for Healthy Ageing Research and deputy head of the School of Immunity and Infection. I will lead the ARUK-MRC Centre for Musculoskeletal Ageing Research from 2012. I teach immunology on the MBChB course and lead a module on the Biology of Ageing in the Bachelor of Medical Science degree"
Specialization: Ageing, Inflammation, Stress and health in old age& Recovery from trauma
Andersen was born in Great Falls, Montana. She earned a doctorate in Neuromolecular Biology at the University of California, Los Angeles (UCLA). She completed a postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital before going to the University of Southern California as an assistant then an associate professor at the Andrus Gerontology Center. She joined the Buck Institute in 2000.
As a renowned expert on Parkinson’s disease, Julie K. Andersen, Ph.D., is pursuing a wide array of leads toward treatments for this complex neurodegenerative disorder. She has identified several early risk signals for Parkinson’s, an age-related illness that causes a progressive decline in movement and muscle control. The symptoms can include shaking hands and difficulty with walking.
Title: Scientist at Buck Institute for Research on Aging
Specialism: biological aging in Parkinson’s disease and identification of novel therapeutic targets for the disease
After three years of postdoctoral research at the University of York, she was Demonstrator, Lecturer, Reader and finally Professor at the University of Edinburgh. After many years in Scotland, in 1994 she became Professor of Biometry, University College London. She is both a founding director of the new Max Planck Institute for Biology of Ageing in Cologne and Director of the UCL Institute of Healthy Ageing.
Linda Partridge’s research is directed to understanding both how the rate of ageing evolves in nature and the mechanisms by which healthy lifespan can be extended in laboratory model organisms. Her work has focussed in particular on the role of nutrient-sensing pathways, such as the insulin/insulin-like growth factor signaling pathway, and on dietary restriction. Her current work is directed to developing pharmacological treatments that ameliorate the human ageing process to produce a broad-spectrum improvement in health during ageing. She is the recipient of numerous awards, including a DBE for services to science. She is founding director of the new Max Planck Institute for Biology of Ageing in Cologne as well as the Director of the UCL Institute of Healthy Ageing.
Title: Professorial Research Fellow, Genetics, Evolution & Environment
Division of Biosciences
Specialism: biology and genetics of ageing (biogerontology)
ge-related diseases, such as Alzheimer's disease and Parkinson's disease
Maria A. Blasco obtained her PhD in 1993 at the Centro de Biología Molecular "Severo Ochoa" under the supervision of M. Salas. That same year, Blasco joined the Cold Spring Harbor Laboratory in New York (USA) as a Postdoctoral Fellow under the leadership of C. W. Greider. As a postdoc she isolated one of the telomerase essential genes and generated the first telomerase deficient mouse model, which served to demonstrate the importance of telomerase in telomere maintenance, chromosomal instability and disease. In 1997, she returned to Spain to start her own research Group at the Centro Nacional de Biotecnología in Madrid. She joined the Spanish National Cancer Research Center (CNIO) in 2003 as Director of the Molecular Oncology Programme and Leader of the Telomeres and Telomerase Group. In 2005, she was also appointed Vice-Director of Basic Research at CNIO. Since June 2011, she is the CNIO Director.
For more than 20 years, Blasco´s work has focused in demonstrating the importance of telomeres and telomerase in cancer, as well as in age-related diseases. Blasco has published more than 250 papers in international journals and has an h-index of 81. Her achievements have been recognized by the following international and national awards: Josef Steiner Cancer Research Award, Swiss Bridge Award for Research in Cancer, Körber European Science Award, the EMBO Gold Medal, the "Rey Jaime I" Award in Basic Research, the Fundación Lilly Preclinical Research Award, and the "Santiago Ramón y Cajal" National Award in Biology. Blasco holds two Doctorate Honoris Causa from the Universidad Carlos III of Madrid and from Universidad de Alicante and in October 2017 she received the Scientific Merit Award of the Generalitat Valenciana.
Title: Director at Spanish National Cancer Research Centre (CNIO)
Maria Konovalenko is a Russian life extension advocate, transhumanist, bioscientist and co-founder of the Longevity Party political organisation. She is a member of the Russian Science for Life Extension Foundation and longevity advisor to Zoltan Istvan's transhumanist party. Current projects include the Longevity Cookbook.
Title: Scientist in Residence at Formic Ventures
Patricia Olson, Ph.D., serves as the Vice President, Discovery & Translation, at the California Institute for Regenerative Medicine (CIRM) responsible for the development, implementation and outcomes of CIRM’s Discovery and Translation funding programs. Previously, she served in a variety of positions at CIRM including Executive Director, Scientific Affairs, responsible for the development, review, implementation and management of CIRM’s research funding program.
Prior to joining CIRM, Dr. Olson served in a variety of positions at Chiron Corporation (now Novartis) including Vice President, Protein Therapeutics Research and Vice President, Portfolio Management and Strategic Planning, R&D. While at Chiron, she participated in the research and development of several products including two marketed products. She is an inventor on 22 issued U.S. patents and an author of 31 peer-reviewed publications and book chapters. Dr. Olson received her Ph.D. in Biochemistry and Biophysics from the University of California at Berkeley and her B.S. in Cellular Biology (magna cum laude) from the University of Michigan, Ann Arbor.
Title: Vice President, Discovery & Translation, at the California Institute for Regenerative Medicine (CIRM)
Polina Mamoshina is a senior research scientist at Insilico Medicine, Inc, a Baltimore-based bioinformatics and deep learning company focused on reinventing drug discovery and biomarker development and a part of the computational biology team of Oxford University Computer Science Department. Polina graduated from the Department of Genetics of the Moscow State University. She was one of the winners of GeneHack a Russian nationwide 48-hour hackathon on bioinformatics at the Moscow Institute of Physics and Technology attended by hundreds of young bioinformaticians. Polina is involved in multiple deep learning projects at the Pharmaceutical Artificial Intelligence division of Insilico Medicine working on the drug discovery engine and developing biochemistry, transcriptome, and cell-free nucleic acid-based biomarkers of aging and disease. She recently co-authored seven academic papers in peer-reviewed journals.
Title: Senior research scientist at Insilico Medicine, Inc
Arielle Burstein is an associate director with the Milken Institute Center for the Future of Aging. She works to accelerate a needed shift in thinking about aging by collaborating with the Center’s leadership and advisors, convening experts, promoting thought leadership and fostering action. Her work spans the topics of the longevity economy, innovation, purpose, and engagement of young people in issues around aging. Burstein shapes research, produces digital communications and manages and contributes to Center publications. She joined the Institute after several years at the Massachusetts Institute of Technology AgeLab, a multidisciplinary research program, where she translated demographic change into innovative social research on aging. Her research has contributed to new products and services in retail, finance, and other industries to improve quality of life as we age. She has published academic research on the subject of technology for caregivers of people with dementia. Burstein holds a bachelor of arts degree in international relations and Hispanic studies from Wheaton College, and she works at the Institute's Santa Monica office.
Title: Associate Director at Milken Institute
Elizabeth Parrish is the Founder and CEO of BioViva Sciences USA Inc. BioViva is committed to extending healthy lifespans using gene therapy, drugs development. To achieve this goal, BioViva has developed a comprehensive set of biomarkers of aging, which include molecular, physiological, anatomical, clinical, and qualitative markers.
Liz is known as "the woman who wants to genetically engineer you," she is a humanitarian, entrepreneur, author and innovator and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of gene therapy, she serves as a motivational speaker to the public at large for the life sciences.
Elizabeth is actively involved in international educational media outreach and is a founding member of the International Longevity Alliance (ILA). She is the founder of BioTrove Investments LLC and the BioTrove Podcasts, found at iTunes, which is committed to offering a meaningful way for people to learn about current technologies. She is also a founding member of the American Longevity Alliance (ALA) a nonprofit trade association that brings together individuals, companies, and organizations who work in advancing the emerging field of cellular and regenerative medicine with the aim to get governments to consider aging a disease.
Title: Founder and CEO at BioViva Sciences USA Inc
Jill Angelo is the CEO and Founder of Genneve whose mission is to improve the lives of women in midlife and menopause. Genneve is a first-of-its-kind online clinic for women in menopause, which uses AI and telehealth technology to improve access to education, practitioners and products personalized for a woman’s symptoms today and long-term care.
Prior to running Genneve, Jill had a 20-year career in technology at both Great Plains Software and Microsoft. Most recently, she spent 15 years at Microsoft in executive roles such as Chief of Staff to the CMO, Director of Global Media, and Product Management for Emerging Markets. Jill recently joined the Board of Directors for Special Olympics of Washginton.
Title: CEO and Founder at Genneve
Katy Fike is a founding partner of Generator Ventures and co-founder of Aging2.0, a global innovation network and startup accelerator program. Katy is a PhD gerontologist, former investment banker and systems engineer. Recently named one of Fast Company’s 100 Most Creative People in Business, Katy is a sought after speaker on topics related to innovation and aging and has been featured in national media including NPR, PBS NewsHour, Bloomberg TV, Wall Street Journal, BusinessWeek, Forbes, TIME, TechCrunch and Huffington Post. Katy has taken the stage at conferences such as South by Southwest, Consumer Electronics Show, Boomer Venture Summit, American Senior Housing Association, National Investment Center for Seniors Housing and Senior Living 100. Katy is on the Board of Directors of the American Society on Aging and the Family Caregiver Alliance. Katy earned her doctorate in gerontology from the USC Davis School of Gerontology and her undergraduate degree in Systems Engineering from the University of Virginia. Katy has taught Gerontology at the university level and her research on care transitions has been published in peer-reviewed journals and presented at several national conferences.
Title: Founding partner of Generator Ventures & Co-founder of Aging2.0
Kristen leads BIOAGE in its mission to develop a broad pipeline of therapies that target aging in order to increase healthspan and address chronic diseases. Kristen draws from a deep background in aging research and systems biology to develop BIOAGE’s data-driven approach to identify and target the molecular pathways that drive aging. Kristen received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University where she was a fellow of the Ellison Medical Foundation / American Federation for Aging Research. She has over 10 years of experience developing novel bioinformatics approaches for data-driven investigation into the mechanisms of aging and age-related disease, with 18 published papers spanning computational drug discovery, biomarkers of aging, and the genetics of exceptional human longevity.
Title: Co-Founder, CEO at BIOAGE
Martha Deevy joined the Stanford Center on Longevity in January, 2009 and serves as Associate Director and Senior Research Scholar, where she focused on re-imagining how we plan for retirement and how we live in retirement. She has over 20 years of management experience in Silicon Valley technology and financial services companies in senior executive positions at Apple, Charles Schwab and Intuit. Having held positions in marketing, business development, product development, strategic planning, finance and IT, she has developed a strong general management background that she successfully used to define and shape the businesses she managed.
Martha has also served on the boards of directors of a number of publicly traded and non-profit organizations. She received an M.B.A. in Finance and Management Information Systems from University of Minnesota and a B.A. in Quantitative Economics from University of Illinois.
Title: Associate Director at Stanford Center on Longevity
Robin Farmanfarmaian is a professional speaker, entrepreneur, and angel investor driving high-level business development for cutting-edge medical and biotech companies poised to impact 100M patients. With over 125 speaking engagements in 12 countries, she educates audiences on technology, the future of healthcare, patient empowerment, building thought leadership, and more.
Keeping within the empowerment theme, Robin also works with executives, entrepreneurs, consultants and physicians who want to become thought leaders in order to accelerate their career and business goals. Her 1st book, “The Patient as CEO: How Technology Empowers the Healthcare Consumer”, is a #1 Best Seller on Amazon. Her 2nd book, ""The Thought Leader Formula"", publishes March 5, 2019.
Title: Professional speaker and entrepreneur
In a health policy career spanning more than 15 years, Suzanne has helped to run multi-stakeholder initiatives in numerous disease areas. She has broad knowledge of the challenges of intersectoral working and the need for sustainable and person-focused healthcare systems.
Having begun her career at IRDES, the French national centre for health economics in Paris, she worked as Global Health Economist at Novartis Pharma and later as Associate Director of Health Outcomes for Europe and the UK at Bristol-Myers Squibb. She went on to become Director of Research at the International Longevity Centre – UK. She was also a founding member of the European Nutrition for Health Alliance, and is a member of the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP).
Suzanne has authored numerous peer-reviewed papers, book chapters and policy reports. She spent five years teaching at the School of Public Policy at University College London, is a former Nuffield Trust Research Fellow at the Judge Institute of Management at Cambridge University, and was Adjunct Professor at the University of Strasbourg.
Suzanne has a Master of Public Health from Columbia University and a PhD in Public Health from the University of Strasbourg. In 2006, she completed a Nuffield Trust-funded post-doctoral fellowship at the University of Cambridge, which looked at benchmarking health systems and public involvement in healthcare.
Title: Managing Director at The Health Policy Partnership Ltd
Tina is founder of Collider Health, a health innovation catalyst that works with organisations of all shapes and sizes to think and do differently and transform health with meaningful impact. Tina is chair of Future Health Collective , a multi-disciplinary, cross-industry group geared to foster collaboration and radical innovation in areas of unmet need in health and social care.
Tina is an ecosystem architect and builds collaborative networks to help corporates, start-ups, third sector and investors form strategic partnerships and facilitate smart investment- for long term, sustainable impact. She has established relationships with leading incubators, accelerators, investors, digital health start-ups, clinical innovators and tech corporates. Tina is currently working with Innovate UK on consortia development for the Industrial Strategy Challenge Fund for Healthy Ageing (£98 million) and the national Academic Health Science Network (AHSN) AI initiative to build the artificial intelligence ecosystem for the NHS.
Title: Founder & CEO at Collider Health
Co-founder and Co-director of People Unlimited, Bernadeane has spoken and written on radical life extension and physical immortality for over four decades. Her speaking style is fiery and focused, challenging conventional limited thinking with visionary insight and common sense honesty.
Bernadeane is an expert in the habits and mindset of living an ageless lifestyle and draws on her own experience to motivate and enlighten others to break out of the box of ageism. A leading advocate for woman and immortality, she has inspired thousands of women to take on greater authority and accountability in their lives, and to look beyond the limitations of traditional roles in death-oriented society in order to redefine themselves for an unlimited future. She's the co-author of Just Getting Started: Fifty Years of Living Forever, appearing on numerous TV shows both domestically and abroad, and has touched audiences in dozens of countries.
Title: Co-founder and Co-director of People Unlimited
Cameron Michelle Diaz is a retired American actress, writer and former model. She has frequently appeared in comedies throughout her career, while also earning critical recognition in dramatic films. Her accolades include four Golden Globe Award nominations, three Screen Actors Guild Award nominations, and a New York Film Critics Award. In 2013, she was named the highest-paid actress over 40 in Hollywood.
Now Cameron continues the journey she began as writer, opening a conversation with her peers on an essential topic that that for too long has been taboo in our society: the aging female body. In The Longevity Book, she shares the latest scientific research on how and why we age, synthesizing insights from top medical experts and with her own thoughts, opinions, and experiences.
The Longevity Book explores what history, biology, neuroscience, and the women’s health movement can teach us about maintaining optimal health as we transition from our thirties to midlife. From understanding how growing older impacts various bodily systems to the biological differences in the way aging effects men and women; the latest science on telomeres and slowing the rate of cognitive decline to how meditation heals us and why love, friendship, and laughter matter for health, The Longevity Book offers an all-encompassing, holistic look at how the female body ages—and what we can all do to age better.
Title: Retired American actress, writer and former model
Dr. Daisy Robinton is a molecular biologist, lifestyle/fitness model. She completed her PhD in Human Biology and Translational Medicine at Harvard University in 2016 and landed on the Forbes 30 Under 30 list in 2017. Daisy was lauded for her extensive research into stem cell and liver cancer treatment, as well as her innovative charity work. Her modeling work has taken her all over the world working for brands like Neutrogena, lululemon, Powerade and Reformation. Daisy’s passion for the effective translation of science has fueled her years of teaching, speaking, and consulting on numerous projects in the US and abroad, leading her to co-found Weird and Wonderful, a production company aimed at bridging the knowledge gap in science by connecting with creativity and entertainment to engage, educate and inspire people from all walks of life.
Daisy's work at Harvard University focussed on researching mechanisms of stem cell identity, with a focus on cancer and developmental biology. Daisy has also founded the 'Science in the News Spring Public Lecture Series' at Harvard to consult people on various biotech start-ups both in the US and the UK.
Title: Co-Founder & CEO at Oviva Therapeutics
Daria Khaltourina, is a Board Member of the International Longevity Alliance and the Chair of the Board of the Russian Regional Russian NGO "Council for Public Health and Demography". She received Ph.D. in anthropology, and after a few years of academic career she gradually moved into the area of public health advocacy, including anti-liquor and anti-tobacco control in Russia and internationally. She currently works at promoting regulation beneficial for biomedical R&D, especially in the area of curing and preventing pathologies of aging. Daria is currently a coordinator of "Healthy Longevity" segment of the Russian National Technological Initiative.
Title: Board Member of the International Longevity Alliance, Chair of the Board of the Russian Regional Russian NGO "Council for Public Health and Demography"
Diana S. Dooley
Diana Dooley began her professional career as an analyst at the State Personnel Board. In 1975, she was appointed to the staff of Governor Jerry Brown for whom she served as Legislative Director and Special Assistant until the end of his term in 1983. Before becoming an attorney in 1995, she owned a successful public relations and advertising agency. Dooley left her private law practice in December, 2000 to accept the appointment as General Counsel and Vice President at Children's Hospital Central California near Fresno where she established an in-house legal services program and directed the Hospital's advocacy, communications and governmental relations programs. In 2010, Diana Dooley was appointed to lead the California Health and Human Services Agency by Governor Jerry Brown. As California’s designated State Unit on Aging, the California Department of Aging (CDA), which is nominally under the auspices of the California Health and Human Services Agency, has prepared the California State Plan on Aging, 2017-2021 with a focus on promoting the independence and well-being of older adults, adults with disabilities, and their families throughout the State. In three public hearings conducted to receive public comments prior to submission of this State Plan, CDA heard directly from older adults, persons with disabilities, family members, advocates, and providers about the unmet needs in their communities.
Dooley is active in civic and community affairs, having served on the Boards of Directors of the UC Merced Foundation, Blood Source of Northern California and The Maddy Institute at California State University, Fresno.
Elena has been a longevity activist and advocate since 2013, when she first started to organize educational events to make new evidence-based methods of healthy life extension more popular.
The last few years have seen Elena leading some successful projects in Russia, aimed at spreading the idea of healthy longevity among decision makers as well as the general public. Several years of lobbying resulted in the inclusion of her propositions in the strategic program documents of the Russian Federation related to the problems of the elderly. She is a co-author of the book “Aging Prevention for All” (in Russian, 2015), where, among other topics, she is sharing how to facilitate the adoption of the healthy lifestyle to promote the period of good health.
Elena is an Honorary Member of the International Longevity Alliance, supporting the various advocacy projects of this group. In 2015, she helped to shape and coordinate the successful crowdfunding campaign of the Major Mouse Testing Program – a study of Senolytic drug combinations on mouse lifespan.
Previously Elena has worked as a project manager in the pharmaceutical and advertisement industries, helping to promote new drugs and therapies. This experience helped her to realize that the existing therapies were not 100% effective and could not completely stop age-related diseases – which has ignited an interest for the development of innovative therapies.
Title: Founder and CEO at Longevity Culture Foundation
Helen Whately is a British Conservative Party politician who has been the Member of Parliament (MP) for the Faversham and Mid Kent constituency in Kent since 2015.
Helen also sat on the Health Select Committee in the 2015-17 Parliament.
Helen has an established career in business and healthcare. For nearly a decade, she has worked with NHS hospitals, helping them improve care and make the most of resources. She has also advised healthcare regulators and commissioners and worked on healthcare policy.
Previously Helen ran a business unit at AOL Time Warner, negotiated deals for AOL Europe and trained as a management accountant at PricewaterhouseCoopers.
Alongside her career, Helen has worked with several charities as a volunteer and advisor and been a school governor.
Title: Member of Parliament for Faversham and Mid Kent & Exchequer Secretary to the Treasury
Joanna Bensz is a Co-founder and CEO at Longevity Institute, a non-profit organization providing an open knowledge platform for identifying, highlighting and supporting solutions to today's healthy longevity sector challenges and opportunities. The Longevity Institute is the first private institute in Poland in the field of healthy aging, healthy lifestyle and the use of the latest scientific achievements, artificial intelligence and blockchain technology in this sector. One of their missions is to create a bridge between business, academia, financial institutions and start-up companies in the area of healthy longevity and health preservation. The Longevity Institute brings together a global community of cross sector experts, organizations and entrepreneurs with an interest in healthy longevity, age science, preventive healthcare and longevity economy.
Joanna has a significant experience in the management and business development of international companies from the industrial and technological sectors in Poland and the region of Central and Eastern Europe. She was associated with the American Chamber of Commerce in Poland for many years.
Joanna has a master's degree in German philology and a diploma in international and strategic marketing at the Dublin Business School in Ireland. She is also a graduate of the AMP management program at the IESE Business School at the University of Navarra in Barcelona and Warsaw.
Title: Co-founder and CEO at Longevity Institute
Kate is a Managing Partner at Longevity Capital as well as a Director of Strategy and Business Development at Deep Knowledge Ventures, Aging Analytics Agency and Deep Knowledge Analytics. She is an experienced corporate attorney by background, licensed to practice law in California (2003), New York (2004) and Russia (2000), with an extensive sales and marketing experience.
Compelled by the paradigm-shifting advances in science and technology in the fields of aging and longevity, Kate enthusiastically joined Deep Knowledge Ventures Group.
Title: Managing Partner at Longevity.Capital
A consultant to several publishing companies, Lindsay is also an award-winning financial journalist and author. Co-founder of MoneyFightClub.com, which offers financial well-being workshops for major British companies. Writes the Money Mentor column for the Weekend Financial Times and appears regularly on Share Radio. Lindsay was a speaker at the Women at the Top Summit in September 2016. She also appeared at the FT Weekend Live Festival.
Lindsay was the first woman to be appointed Business Editor of The Times and subsequently moved into newspaper and magazine management.
She is also the deputy chair of the Citizens Advice Bureau in West Sussex.
She is the co-author of Money Fight Club (Harriman House) with Anne Caborn, a practical guide to saving money the smart way and tackling the High Street rip-offs - from supermarkets to banks and insurance companies. She has also launched a website: moneyfightclub.com, which has loads of resources including downloadable letters of complaint for a wide range of problems.
She also wrote Working Mum: The Survival Guide helping parents to find their way through the intricacies of flexible working and employment law and The Money Diet: Three Months to Financial Fitness, which was serialised in three newspapers.
Lora Connolly is director of the California Department of Aging, which administers the Older Americans Act services through the state’s 33 Area Agencies on Aging, as well as the Medicaid HCBS Waiver (which annually serves approximately 11,000 older adults), and certifies more than 240 Adult Day Health Care Centers for Medicaid participation. The California Department of Aging developed the current State Plan on Aging 2017-2021 with a focus on promoting the independence and well-being of older adults, persons with disabilities, and their families. The State Plan outlines specific goals, objectives, and strategies that CDA believes it can achieve with existing resources.
For the past 16 years, Connolly has also co-managed a series of federal Administration on Aging Dementia Grants, in partnership with the state’s regional Alzheimer’s organizations.
When Gavin Newsom, California’s new governor, began his term among a growing crisis of senior poverty in the state, Connolly served as coauthor of Governor Newsom's Master Plan on Aging, one of his top three priorities mentioned in his State of the State Address.
Maggie Throup is a British Conservative Party politician. A former biomedical scientist, she was first elected as the Member of Parliament (MP) for Erewash in the 2015 general election. She was re-elected in the 2017 general election.
After graduating she worked as a biomedical scientist at the Calderdale Health Authority for seven years. During her time there, she became a Fellow of the Institute of Biomedical Science specialising in haematology. She then pursued a career in marketing and public relations which included a directorship of a pharmaceutical company and running her own consultancy.
She was employed as a director in the In-Vitro Diagnostics Division of a pharmaceutical company for ten years. She also has 19 years of experience as a business consultant, mainly in marketing based on quantitative and qualitative market research, and has run her own successful marketing consultancy since 1996.
In addition to her professional successes, Throup has contributed to overseas development in Rwanda and held voluntary non-executive roles with Solihull-based charities, including Changes UK. She is a trustee of the Carers Centre as well as Drug Rehabilitation CIC, which she also chairs.
Title: British Conservative Party politician
Natasha Vita-More is a PhD researcher University of Plymouth, Faculty of Arts, School of Art and Media; holds a MPhil, University of Plymouth, Faculty of Technology, School of Communications, Computers and Electronics; an MSc, University of Houston, Future Studies, Social Sciences and Humanities; a BFA, University of Memphis, Painting, Sculpture and Printmaking; was filmmaker-in-residence, University of Colorado; and holds Certificates in Nutrition and Sports Training, American Muscle & Fitness Association.Natasha’s research concerns the aesthetics of human enhancement and radical life extension, with a focus on sciences and technologies of nanotechnology, biotechnology, information technology, and cognitive and neuro sciences (NBIC). Currently Executive Director of Humanity+, Inc., a 501c3 non-profit educational organization, she is focusing on conferences, prizes, and addressing what it means to be human in an AI-driven world.
On the academic side, she is Senior Professor of graduate and undergraduate programs at the University of Advancing Technology, and has lectured at Harvard, Stanford, Virginia Commonwealth, Cambridge (UK) Aalto (Finland), and Polytechnic (Hong Kong) universities. Natasha continues to work with academic institutions, non-profit organizations and business about human futures. She is a track adviser at the Singularity University, on the Scientific Board of Lifeboat Foundation, a Fellow of the Institute for Ethics and Emerging Technologies, Visiting Scholar at 21st Century Medicine, and advises non-profit organizations including Adaptive A.I. and Alcor Life Extension Foundation. She has been a consultant to IBM on the future of human performance.
Title: Author, Scientist & Innovator. AI, Nanotech + Longevity & Founder at Center for Transhumanist Studies
Suzanne Somers (born Suzanne Marie Mahoney, October 16, 1946) is an American actress, author, singer, businesswoman, and health spokesperson. She appeared in the television role of Chrissy Snow on Three's Company and as Carol Foster Lambert on Step by Step.
Somers later became the author of a series of self-help books, including Ageless: The Naked Truth About Bioidentical Hormones (2006), about bioidentical hormone replacement therapy. She has released two autobiographies, four diet books, and a book of poetry.
She has been criticized for her views on some medical subjects and her advocacy of the Wiley Protocol, which has been labelled as "scientifically unproven and dangerous". Her promotion of alternative cancer treatments has received criticism from the American Cancer Society. Suzanne Somers is a regular keynote presenter at RASDFest.
Title: Owner at Suzanne Organics
Hilary Camilla Cavendish, Baroness Cavendish of Little Venice (born 20 August 1968) is a British journalist and former Director of Policy for Prime Minister David Cameron. Cavendish became a Conservative Member of the House of Lords in Cameron's resignation honours, but resigned the party Whip in December 2016 to sit as a non-affiliated peer. From 2002 until 2012 she worked at The Times where she was Associate Editor, columnist and in 2010 Chief Leader Writer.
She then moved to The Sunday Times from 2012 to May 2015. She has worked as a McKinsey management consultant, an aid worker, and as an aide to the CEO of Pearson plc.
She helped to found the lobby group London First, and was the first CEO of the not-for-profit trust South Bank Employers' Group, which masterminded the regeneration of the South Bank of the Thames in the late 1990s.
From May 2015 to July 2016, Cavendish was head of the prime minister's policy unit at No10 Downing Street in succession to Jo Johnson. Amongst initiatives, Cavendish is credited with persuading the Prime Minister and his Chancellor about the benefits of a sugar tax; she said that the "link between sugary drinks and obesity are clear and stark". The Soft Drinks Industry Levy came into force in April 2018.
Camilla Cavendish is an award-winning writer and broadcaster, and Senior Fellow at Harvard’s Kennedy School. She writes a weekly oped column on current affairs for the Financial Times and is the author of “Extra Time: Ten Lessons for an Ageing World”, published by Harper Collins in May 2019. She has been Head of the Prime Minister’s Policy Unit under David Cameron, a Non-Executive Director of the Care Quality Commission, and a McKinsey consultant. She chairs the non-profit Frontline and sits in the House of Lords as an independent peer: Baroness Cavendish of Little Venice. HarperCollins published Cavendish's first book Extra Time in May 2019.
Title: Harvard senior fellow; FT weekly columnist; author "Extra Time: Ten Lessons for an Ageing World"; ex-director, Downing Street Policy Unit
Hannah-Beth Jackson is an American politician currently serving in the California State Senate. A Democrat, she represents the 19th Senate District, encompassing Santa Barbara County and most of Ventura County.
Jackson served as Chair of the California Legislative Women's Caucus from 2015 to 2016. She is also a member of the California Legislative Jewish Caucus. Jackson is a former prosecutor, the co-founder of two nonprofit organizations, and also served as an adjunct professor at Antioch University.
In May 2019, Hannah-Beth Jackson to prepare for California’s rapidly growing population of aging adults and protect them from falls has authored two bills. Senate Bill 228 will establish a Master Plan for Aging Californians and Senate Bill 280 will help aging and disabled adults make home modifications to reduce their risk of dangerous and often life-threatening falls. Senator has also introduced Senate Resolution 39 to declare May as Older Americans Month and raise awareness about the contributions of California’s older adults as well as the challenges they continue to face.
Title: Former California State Representative
Edwina Rogers (born May 27, 1964) is an American lobbyist and former White House staff member. She is the founder and CEO of the Global Healthspan Policy Institute, the founding Executive Director and current President of the Secular Policy Institute, the CEO of the Center for Prison Reform, and a partner at the law firm of Johnson, Rogers and Clifton.After graduation from law school, Rogers worked on international trade for President George H. W. Bush at the Department of Commerce from 1989 to 1991. She practiced law in the Washington office of Balch and Bingham from 1991 until 1994, then served as General Counsel of the National Republican Senatorial Committee during the Republican take-over of the Senate in 1994. She worked for Senator Trent Lott while he was the Senate Majority Leader in 1999.
She was an Economic Advisor for President George W. Bush at the White House during 2001 and 2002 at the National Economic Council, focusing on health and social security policy. Rogers handled health policy for Senator Jeff Sessions in 2003 and 2004 before serving as Vice President of the Health Policy for the ERISA (Employee Retirement Income Security Act of 1974) Industry Committee (ERIC) in Washington, DC from May 2004 until January 2009. ERIC advocates the employee benefits and compensation interests of America’s major employers.
She worked with Senator Paul Coverdell to establish the Fair Government Foundation, a non-profit, non-partisan organization established to research and educate the public on First Amendment rights, campaign finance and political action committees, lobbying, government ethics and election law fairness issues.
Title: Attorney and Government Affairs, CEO Global Healthspan Policy Institute
Nancy, an alum of Leadership Southern California 2016, is the State Director for AARP. Two years ago Nancy was enticed to move back to her home state as the interim state director for AARP, and the challenge became inspiration. She was responsible for creating a new vision for AARP’s work, new relationships with state leaders, and burgeoning work in local communities – skills that are now honed in Leadership Southern California’s revised curriculum focused on leading collaboration and building strategic partnerships.
AARP is a nonprofit, nonpartisan organization, with a membership of nearly 38 million that helps people turn their goals and dreams into 'Real Possibilities' by changing the way America defines aging. With staffed offices in all 50 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, AARP works to strengthen communities and promote the issues that matter most to families such as healthcare security, financial security and personal fulfillment. AARP also advocates for individuals in the marketplace by selecting products and services of high quality and value to carry the AARP name. As a trusted source for news and information, AARP produces the world’s largest circulation magazine, AARP The Magazine and AARP Bulletin. AARP does not endorse candidates for public office or make contributions to political campaigns or candidates.
Title: State Director at AARP
Dr. Conboy received her Ph.D. in Cellular and Molecular Immunology from Stanford University in 1998. Dr. Conboy is an assistant professor of bioengineering at UCB, and she joined the department in November of 2004. Her research is focused on the cellular signaling pathways that control the behavior of adult stem cells and understanding the age-related changes that affect this signaling. She is also an experienced rodent researcher and pioneered some of the early parabiosis research examining the role of signaling factors in aging and tissue regeneration.
Since 2005, she has been a faculty mentor for the UC Berkeley chapter of the Student Society for Stem Cell Research and a sponsor of the DeCal class Stem Cells: Science and Society. She is also a reviewer for the CIRM training grant program at UC Berkeley and a member of the peer review committee for the state of Maryland’s stem cell initiative, an invited peer reviewer for the Neurogenesis and Cell Fate Study Section at the NIH, and a reviewer for the Nathan Shock Center of Excellence in the Basic Biology of Aging. Irina Conboy received the CIRM New Faculty Award in 2008, the Glenn Award for Research in Biological Mechanisms of Aging in 2008, and the New Scholar in Aging award from Ellison’s Medical Foundation in 2005.
Title: Professor at the University of California, Berkeley in the Department of Bioengineering
Judith Campisi is an American biochemist and cell biologist. She is a professor of biogerontology at the Buck Institute for Research on Aging. She is also a member of the SENS Research Foundation Advisory Board and an adviser at the Lifeboat Foundation. She is co-editor in chief of the Aging Journal, together with Mikhail Blagosklonny and David Sinclair, and founder of the pharmaceutical company Unity Biotechnology. She is listed in Who's Who in Gerontology. She is widely known for her research on how senescent cells influence aging and cancer — in particular the senescence-associated secretory phenotype (SASP)
Title: Professor of biogerontology at the Buck Institute for Research on Aging
Lisa Fabiny Kiser
Lisa Fabiny Kiser, Vice President of Operations at SENS Research Foundation, is a Bay Area transplant from the Midwest and a dedicated scientist and administrator. Lisa’s educational background is in the Life Sciences, in which she earned her Bachelor’s Degree from Otterbein College in 2009. Her industry experience ranges from microbiology, stem cell analytics, flow cytometry, to quality assurance, finance, operations, and HR.
Lisa joined SRF in 2010 as a volunteer in the laboratory, and was hired on in the administrative department in early 2012, where she excelled in finance and operations. She is invested in advancing rejuvenation biotechnologies and using her skills in organizational management to move SRF forward in this burgeoning field. Lisa currently spends her time running the operations and outreach departments at SRF – adding fundraising, event planning, and marketing to her current skill set. She hopes to continue to help SRF lead the charge in advancing rejuvenation biotechnology against the diseases of aging through funding research, forming new therapies, influencing global health policy, and creating a dialogue between top scientists and regulators in the industry.
Title: Vice President of Operations at SENS Research Foundation
Maria Entraigues Abramson
Maria Entraigues-Abramson (also known professionally as María María) is an Argentine-American singer, composer, and actress, and is the Global Outreach Coordinator for the SENS Research Foundation.
As the outreach coordinator for the SENS Research Foundation, Entraigues has represented the Foundation internationally at conferences and in the media, and has explained and promoted the Foundation's goals of eradicating the diseases and disabilities of aging through innovative biotechnologies, including presentations at conferences internationally. Entraigues is also one of "The 300 Members of Methuselah Foundation", a group of people committed to help the advancement of technologies to eradicate the needless suffering of age-related disease and extend healthy human life.
Entraigues serves as the Global Outreach Coordinator for the SENS Research Foundation, and is also part of the Advisory Team of the Coalition for Radical Life Extension, a Board Member of the International Longevity Alliance,Director of Communications for the California Transhumanist Party, and a member of the Advisory Board of the Lifeboat Foundation.
Title: Argentine-American singer, composer, and actress & Global Outreach Coordinator for the SENS Research Foundation
Sarah Thomas joined the Aging2.0 team as the Genesis Innovation Fellow. Serving also as Director of Global Innovations for Genesis Rehabilitation Services/Genesis Healthcare, one of the largest post-acute care providers in the country, Sarah is passionate about innovation and improving the lives of older adults.
Sarah has dedicated 15 years to aging services, including five years consulting for emerging technology companies. Most recently, she served as the Legislative Affairs Liaison for Hallmark Rehabilitation. Sarah combines her Occupational Therapy background with her operational, clinical and entrepreneurial experience to inspire passionate changes to the current systems in the elder care environment.
Sarah currently is appointed to the Administration and Management Special Interest Section Committee for the American Occupational Therapy Association, an active member of LeadingAge, the California Association of Healthcare Facilities, and is on the Telehealth workgroup for The National Association for the Support of Long Term Care. She is a contributing author for the recent book Readmission Prevention – Solutions Across the Provider Continuum by Josh D Luke and is a sought-after speaker for national conferences.
Title: Genesis Innovation Fellow at Aging2.0, Director of Global Innovations for Genesis Rehabilitation Services/Genesis Healthcare
Tanya Jones is the Chief Executive Officer and co-founder of Arigos, a startup that is developing a methodology for the long term banking of organs for the transplant industry and the Chief Operating Officer of SENS Research Foundation, a nonprofit working to research, develop and promote comprehensive regenerative medicine solutions for the diseases of aging.
As the CEO of Arigos, Tanya Jones secured early funding for Arigos, including becoming the first company funded by Breakout Labs, the Thiel Foundation’s most recent effort to effect disruptive innovation in science and technology. She is currently in the process of securing another round of funding which will enable Arigos to complete proof-of-concept recovery experiments on human-scale organs stored at liquid nitrogen temperatures.
As the COO of SENS Research Foundation, Tanya manages the contracts and financing for its collaborative extramural research projects with such leading research institutions as Harvard, Cambridge, Yale, Oxford, Wake Forest Institute for Regenerative Medicine, The Buck Institute for Research on Aging, and Rice University. In addition, she leads the strategy and execution of the Foundation’s finance, human resources and real estate activities.
Title: Chief Operating Officer at Zeden
Laura Deming is the daughter of John and Tabitha Deming; she grew up in New Zealand. Deming and her brother, Trey, were homeschooled; she says she taught herself "calculus and probability and statistics, and French literature and history." At age 8, Deming became interested in the biology of aging, and at age 12 she joined the lab of Cynthia Kenyon at the University of California, San Francisco.Kenyon successfully increased the lifespan of the worm C. elegans by a factor of ten through genetic engineering.Deming was accepted to MIT at age 14 and studied physics,but later dropped out to accept the $100,000 Thiel Fellowship and start a venture capital firm.Deming was one of only two women in the 2011 initial class of Thiel Fellows. Deming is a partner at and founder of The Longevity Fund, a venture capital firm focused on aging and life extension.The firm raised $4 million in its first fund and $22 million for its second fund, in 2017. The Longevity Fund investments include Unity Biotechnology, which develops senolytic drugs targeting diseases of aging, Navitor Pharmaceuticals, and Metacrine. In 2018, Deming launched Age1, a four-month startup accelerator program focused on founders creating longevity companies.The program graduated its first class of six on October 10, 2018, with companies including Fauna Bio, a startup using the biology of hibernation to aid in heart attack and stroke recovery, and Spring Discovery, focused on accelerating aging therapeutic research with machine learning. In August 2018, Deming also began advising the newly launched Pioneer Fund, a fund designed to find talent and "lost Einsteins" around the world, for projects in longevity.
Maria Owings Shriver (born November 6, 1955) is an American journalist, author, a member of the Kennedy family, former First Lady of California, and the founder of the nonprofit organization The Women's Alzheimer's Movement. She was married to former Governor of California and actor Arnold Schwarzenegger, from whom she filed for divorce in 2011. Shriver has received a Peabody Award and was co-anchor for NBC's Emmy-winning coverage of the 1988 Summer Olympics. As executive producer of The Alzheimer's Project, Shriver earned two Emmy Awards and an Academy of Television Arts & Sciences award for developing a "television show with a conscience". Her mother, Eunice Kennedy Shriver, was a sister of John F., Robert and Ted Kennedy. Shriver is currently a "special" anchor and correspondent for NBC News.
Title: NBC journalist and author who founded the Women’s Alzheimer’s Movement
Rebecca Hughes is the Executive Director at Aging2.0, which strives to accelerate innovation to address the biggest challenges and opportunities in aging. Aging2.0’s international, interdisciplinary and intergenerational community has grown to 40k+ innovators across 20+ countries. Their volunteer-run chapter network, which spans 80+ cities, has hosted more than 550 events around the world to bring attention to their mission, educate others and find solutions around the Grand Challenges and opportunities in aging.
Rebecca Hughes responsibilities span across multiple focus areas, including the oversight our chapter community, corporate partners and operations. Over the course of the four years she has been part of the Aging2.0 team, Rebecca has developed a passion and appreciation for aging innovation. She looks forward to continued work within the space.
Title: Chief Of Staff at Agetech News
Sally Greengross is interfaith leader; Islamic and Afghan studies professor; Freelance author writing for a variety of mediums; Mentorship/coaching passion; Non-profit work for military families and education He teaches, podcast, and speaks internationally about Islam and the Qur'an to help people understand the religion and to answer the questions they has about Muslim cultures. In June 2017 he published a chronological modern-English interpretation of the Quran. It received the Gold Medal from NATIONAL INDIE EXCELLENCE AWARDS.
Sally Greengross is interfaith leader; Islamic and Afghan studies professor; Freelance author writing for a variety of mediums; Mentorship/coaching passion; Non-profit work for military families and education He teaches, podcast, and speaks internationally about Islam and the Qur'an to help people understand the religion and to answer the questions they has about Muslim cultures. In June 2017 he published a chronological modern-English interpretation of the Quran. It received the Gold Medal from NATIONAL INDIE EXCELLENCE AWARDS.
Title: Interfaith leader; Islamic and Afghan studies professor; Freelance author writing for a variety of mediums/Editor
In 1987, Russell completed his Ph.D. in Biological Chemistry from the Imperial College of Science and Technology, University of London. Russell also served as a NATO Research Fellow in Chemistry at MIT (Massachusetts Institute of Technology) from 1987-1989. Professor Russell joined CMU as the Highmark Distinguished Career Professor in 2012 to launch and direct the Disruptive Health Technology Institute. He joined the Department of Chemical Engineering in 2017. Prior to coming to CMU Professor Russell was the Founding Director of the McGowan Institute for Regenerative Medicine and Chairman of the Department of Chemical Engineering at the University of Pittsburgh. Dr. Russell has founded three biotechnology companies and was also the Founding President of the Tissue Engineering and Regenerative Medicine International Society. Dr. Russell was the longest serving member of the Science Board to the Food and Drug Administration and Chaired the 10-year scientific review of the Center for Devices and Radiologic Health, publishing the key “Protecting the core of CDRH regulatory science in the face of financial and strategic threats” report. Dr. Russell has served many scientific roles for the Department of Defense, including working for the Defense Health Board and being the founding Co-Director of the Armed Forces Institute for Regenerative Medicine. For the last 25 years, the Russell laboratory has been discovering what can be achieved by exploiting the rich interface of chemistry, biology and materials. Dr. Russell’s work has impacted fields as diverse as chemical and polymer synthesis to tissue engineering and homeland defense. Dr. Russell has pioneered how to make polymers from enzymes and how to incorporate enzymes into bulk polymers. In a series of discoveries Dr. Russell’s laboratory has found how to meld the synthetic and biological worlds.
Title: Vice President, Biologics at Amgen
Dr. Zhavoronkov is the CEO of Insilico Medicine, a Baltimore-based leader in the next-generation artificial intelligence and blockchain technologies for drug discovery, biomarker development, and aging research. At Insilico he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties. He set up the R&D centers in 6 countries including Korea, Russia, and Taiwan and launched multiple biomarker initiatives including Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and diversity.AI initiative.
Since 2012 he published over 80 peer-reviewed research papers and books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy”. He is also the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at EMBO/Basel Life, one of Europe's largest industry events in drug discovery.
Dr. Zhavoronkov holds two bachelor degrees from Queen’s University, a master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University.
Notes on COVID-19:
Zhavoronkov recently made an impact with his proposals for clinical trials with low-dose rapamycin to protect elderly from COVID-19.
Title: Founder and CEO at Insilico MedicineInsilico
Researcher of the laboratory of epigenetics of the Institute of Gerontology of the National Academy of Medical Sciences of Ukraine Alexander Kolyada - a graduate of the biological faculty of the Kiev National University T. Shevchenko. His laboratory was the first to establish the length of telomeres in the genes of Ukrainians, a universal marker of human biological age.
Title: CSO and co-founder in Diagen Lab
Andrew Scott was educated at Firs Farm Primary School and Haberdashers’ Aske’s, Elstree. He attended Trinity College, Oxford where he graduated with a First with Prizes in Politics, Philosophy and Economics in 1987. He received a M.Sc in Economics from the London School of Economics in 1990 and was elected to a Prize Fellowship to All Souls College, Oxford in 1990. He was elected in the same year as philosopher Robert Rowland Smith and historian Scott Mandelbrote. He received his D.Phil (Essays in Aggregate Consumption) from Oxford in 1994. He worked briefly as an economist for Credit Suisse First Boston before holding research positions at London Business School and the London School of Economics. He then took up a lectureship at Oxford University, a Visiting Assistant Professor at Harvard before joining London Business School where he is currently Professor of Economics having previously served as Deputy Dean. Alongside his academic career Scott has been a Non-Executive Director for the UK’s Financial Services Authority and an advisor to the House of Commons, the Bank of England, and H.M.Treasury. He is currently on the advisory board of the UK’s Office for Budget Responsibility and a member of the Cabinet Office Honours Committee (Science and Technology). Most of Scott’s published academic work has focused on macroeconomic fluctuations – originally on business cycles (with a number of joint papers with Daron Acemoglu) then on monetary policy and most recently on fiscal policy and government debt management (with a number of joint papers with Albert Marcet). More recently his work has been on longevity and focusing on the positive economic, social and personal effects that arise from the fact that on average we are living longer and healthier for longer. This focus on the positive aspects of longevity is an offset to the focus on the negative aspects of an ageing society.
Title: Co-Founder at The Longevity Forum
Antonei B. Csoka
Antonei Benjamin Csoka, Ph.D. is a biogerontologist at Howard University who works on the molecular biology of aging, regenerative medicine and epigenetics.
Dr. Csoka earned a bachelor's degrees at Newcastle University in Genetics. He has a master's in Molecular Pathology from University of Leicester and a PhD in Cellular and Molecular Biology from University of Debrecen.
He was a member of the consortium that identified the Lamin A gene as the cause of the accelerated aging disease Hutchinson–Gilford progeria syndrome and participated in the first National Institutes of Health - Progeria Research Foundation workshop. He also showed that Progeria is a true representation of aging with respect to cellular signaling pathways, and truly recapitulates the normal aging process at the cellular level. He currently researches the molecular etiology of aging at the level of signaling pathways.
Dr. Csoka is a prominent proponent of life extension, cryonics and transhumanism, identified as one of the top twenty-three socially connected professors on Twitter. He is a scientific advisor to the Alcor Life Extension Foundation, the UK Cryonics and Cryopreservation Research Network, and the Lifeboat Foundation, a fellow of the Global Healthspan Policy Institute, and was featured in the first Immortality Institute film, Exploring Life Extension (2005) produced by Bruce Klein.
Title: Associate Professor at Howard University
Brian K. Kennedy is the former President and CEO of the Buck Institute for Research on Aging in Novato, California. Having started in July, 2010, Kennedy was asked to resign in October 2016. Kennedy's resignation raised serious questions about Buck Leadership.
Kennedy has published over 80 manuscripts in prestigious journals including Cell, Nature, Science, Genes & Development, and PNAS. Potential public health benefits claimed in one study were questioned by the UK National Health Service in 2014.
Kennedy has served on the NIH Cellular Mechanisms of Aging and Development study section since 2006, acting as Committee Chair since 2010. He has also served on the grant review committee for American Federation for Aging Research Grants since 2006. He has acted as an Associate Editor for the Journal of Gerontology: Biological Science since 2006 and Cell Cycle since 2010. Currently, he is co-Editor-in Chief of Aging Cell. Kennedy has served as a consultant for Biotech and Pharmaceutical companies and is a co-Founder of the Nuvita Animal Health Corporation, a now defunct dog food company. He is also Chairman of Mount Tam Biotechnologies, which is traded as a penny stock. In August 2016, Mount Tam Biotechnologies merged with Tabacalera Ysidron, a defunct cigar company which had failed in its plan to distribute Nicaraguan cigars
Title: Professor at Buck Institute for Research on Aging
Ames, raised in New York City, is a graduate of the Bronx High School of Science. His undergraduate studies were at Cornell University in Ithaca, New York, and his graduate studies were completed at the California Institute of Technology.
Ames was elected a Fellow of the American Academy of Arts and Sciences in 1970.
He is a recipient of the Bolton S. Corson Medal in 1980, Tyler Prize for Environmental Achievement in 1985, the Japan Prize in 1997, the National Medal of Science in 1998 and the Thomas Hunt Morgan Medal in 2004, among many others.
His research focuses on cancer and aging and he has authored over 550 scientific publications. He is among the few hundred most-cited scientists in all fields.
Ames' current research includes identifying agents that delay the mitochondrial decay of aging, understanding the role of mitochondrial decay in aging, particularly in the brain, optimizing micronutrient intakes in the population to prevent disease, malnutrition, and obesity. He is also interested in mutagens as they relate to cancer prevention and aging.
Dr. Ames received more than $650,000 in support from the National Foundation for Cancer Research between 1998 and 2007.
Title: Professor of Biochemistry and Molecular Biology Emeritus at the University of California, Berkeley
Caleb Finch, PhD, researches the basic mechanisms in human aging with a focus on inflammation. He has received most of the major awards in biomedical gerontology, including the Robert W. Kleemeier Award of the Gerontological Society of America in 1985, the Sandoz Premier Prize by the International Geriatric Association in 1995, and the Irving Wright Award of AFAR and the Research Award of AGE in 1999. He was the founder of the NIA-funded Alzheimer Disease Research Center in 1984 and currently serves as co-Director. Finch became a University Distinguished Professor in 1989, an honor held by sixteen other professors at USC who contribute to multiple fields. He is a member of five editorial boards and has written 575 articles and five books, including The Role of Global Air Pollution in Aging and Disease. A new research area is the effect of air pollution on brain development and aging, which he is developing through a USC-wide network (AirPollBrain website).
His area of research includes:
Basic mechanisms in the human biology of aging, with focus on inflammation and nutritional influences;
Air pollution influences on aging;
Evolution of the human lifespan and diseases of aging, especially Alzheimer disease
Title: Professor at the USC Davis School of Gerontology
David Botstein (born 8 September 1942) is an American biologist serving as the chief scientific officer of Calico. He served as the director of the Lewis-Sigler Institute for Integrative Genomics at Princeton University from 2003–2013, where he remains an Anthony B. Evnin Professor of Genomics.In 1998, Botstein and his postdoctoral fellow Michael Eisen, together with graduate student Paul Spellman and colleague Patrick Brown, developed a statistical method and graphical interface that is widely used to interpret genomic data including microarray data. He has subsequently worked on the creation of the influential Gene Ontology with Michael Ashburner and Suzanna Lewis. He is one of the founding editors of the journal Molecular Biology of the Cell, along with Erkki Ruoslahti and Keith Yamamoto. In 2013, Botstein was named Chief Scientific Officer of Google's longevity health startup Calico.
Title: Chief Scientific Officer of Calico
Eric Topol, M.D. is professor of genomics and holds the Scripps endowed chair in innovative medicine. He is the director of the Scripps Translational Science Institute in La Jolla, California. Previously, he led the Cleveland Clinic to its #1 ranking in heart care, started a new medical school, and led key discoveries in heart disease. He lives with his family in La Jolla,California.
Title: Founder and Director, Scripps Research Translational Institute at The Scripps Research Institute
Dr. Eric M. Verdin, M.D. has been Chief Executive Officer and President of Buck Institute For Age Research since November 18, 2016. Dr. Verdin served as an Associate Director and Senior Investigator at the Gladstone Institute of Virology and Immunology and a Professor of Medicine at the University of California. Dr. Verdin's laboratory is the role of protein acetylation in biological processes, particularly in modulating the immune response. Specifically, his laboratory studies histone deacetylase enzymes (HDACs) that remove acetyl groups from histones and non-histone proteins.
Title: Chief Executive Officer and President of Buck Institute For Age Research
Gordon Lithgow received his PhD in Genetics from the University of Glasgow, Scotland. He completed postdoctoral training at the Institute for Behavioral Genetics at the University of Colorado, Boulder. Lithgow was a Senior Lecturer in Molecular Gerontology at the School of Biological Sciences at the University of Manchester in England before coming to the Buck Institute in 2001. He is the Principal Investigator and Director of the Buck Institute’s Interdisciplinary Research Consortium on Geroscience. He is also the Principal Investigator of the Larry L. Hillblom Network on the Chemical Biology of Aging, and is the Coordinator of the Hillblom Center for the Biology of Aging Support Award.
Lithgow sheds light on the mechanisms of aging by identifying agents that extend lifespan or prevent age-related disease. He has discovered a range of factors that can lengthen life in the microscopic worm Caenorhabditis elegans, and he applies these findings to studies in human cell cultures. Much evidence points to stress contributing to a breakdown in the ability to maintain optimal molecular stability resulting in aging and disease. Certain life-extending agents help C. elegans respond to lifelong stress by remodeling the natural stress fighting cellular mechanisms, the Lithgow lab has found. The Lithgow lab has discovered that certain cell proteins capable of extending life can also be closely involved in disease prevention. But when proteins play such dual roles, they may sometimes make tradeoffs that affect the fate of the organism. Dr. Lithgow is studying genetic variations in “checkpoint proteins’’ that may create a trade-off between the rate of aging and incidence of cancer. His area of interest includes uncovering genes and small molecules that prolong lifespan through enhanced molecular stability.
Title: Professor at The Buck Institute
Gregory M. Fahy is Vice President and Chief Scientific Officer of 21st Century Medicine and serves on the company’s Board of Directors. Dr. Fahy prioritizes, develops and directs the company’s research activities. He also manages extramural collaborative research projects.
Dr. Fahy applies his 30+ years of experience in the field of cryobiology and cryopreservation to all research here at 21CM. As a scientist with the American Red Cross, he was the originator of the first practical method of Cryopreservation by vitrification and the inventor of computer based systems to apply this technology to whole organs. Before joining 21st Century Medicine, he was Chief Scientist for Organ, Inc and of LRT, Inc.
Prior to that he was Head of the Tissue Cryopreservation Section of the Transfusion and Cryopreservation Research Program of the U.S. Naval Medical Research Institute in Bethesda, Maryland where he spearheaded the original concept of ice blocking agents. Respected for his expertise and contributions to the advancement of Cryobiology technologies and applications, Dr Fahy is a frequent speaker at national and international scientific meetings and workshops.
A native of California, Dr. Fahy holds a Bachelor of Science degree in Biology from the University of California at Irvine and a Ph.D. from the Medical College of Georgia in Augusta.
He currently holds a joint appointment as a visiting scholar in the Department of Biochemistry at the University of California at Riverside. His scholarly work is highly published and he holds more than 15 patents
Title: Vice President and Chief Scientific Officer at Twenty-First Century Medicine, Inc
Specialism: Cryobiology & Biogerontology
Jan van Deursen
Jan is passionate about basic medical research and its potential to transform human health and treatment of disease. He has a longstanding interest in questions related to cell cycle control and cellular responses to stress. He helped establish the concept that, with aging and development of age-related disease, wasteful transformed cells that cannot divide litter tissues and organs in small numbers and demonstrated that clearance of these so-called “senescent cells” extends both healthspan and lifespan. During his Ph.D. training, Jan pioneered technologies to knock down the expression of endogenous genes in mice, and these techniques have proven to be particularly useful in uncovering the physiological function of mammalian genes essential to cell division or viability. In applying these technologies to address the longstanding question as to whether aneuploidy is a cause or a consequence of cancer, Jan discovered that BubR1 (an essential mitotic checkpoint protein that ensures faithful chromosome segregation) is causally implicated in cancer, progeria and aging. Studies originating from his desire to understand these mechanisms are credited with providing the first in vivo evidence that p16-positive senescent cells drive aging and age-related disease, thus establishing cellular senescence as a promising target for therapeutic intervention. Dr. van Deursen holds a B.S. in Biology, M.S. in Molecular Biology, and Ph.D. in Cell Biology from University of Nijmegen. He is the Vita Valley Professor of Senescence at Mayo Clinic, where he chairs the Department of Biochemistry and Molecular Biology, and directs research programs in the Center for Biomedical Discovery, the Comprehensive Cancer Center, and the Kogod Center on Aging. He is an Honorary Professor at the University of Groningen, the Netherlands and serves on numerous national and international grant review panels.
Title: Co-Founder Unity Biotechnology, Cancer & Aging Scientist & Entrepreneur
1975-1993 Assistant/Associate Professor, Department of Cell Biology/Neuroscience, UT Southwestern.
1993 - Professor, Department of Cell Biology, UT Southwestern, Southland Financial Corporation Distinguished Chair in Geriatric Research.
2002 - Associate Director, Education and Training, UT Southwestern Harold Simmons Comprehensive Cancer Center.
His research interest includes:
Cancer stem cells;
Cell Biology of the cancer genome;
Mechanisms of cellular immortalization;
Mouse models of radiation-induced cancer;
Role of telomeres and telomerase in cancer and aging.
Professor Jerry Shay of the Shay/Wright lab is perhaps most well-known for his research on telomeres and telomerase and their relation to cancer and aging. He has been instrumental in the development of telomerase inhibitors, which turn off the expression of telomerase in cancer cells; this expression is one way in which cancer cells become immortal and divide constantly. His team is also developing another treatment, a small molecule that can uncap the telomeres of cancer cells.
Title: Professor at UT Southwestern
Leonard Guarente, Ph.D., is a founder of Elysium and the company’s chief scientist, a role in which he directs research and product development. Since 1982 he has led the Glenn Center for the Biology of Aging Research at MIT, where his research has focused on the genetic and molecular basis of aging — first in model organisms and now in mouse models and humans.
Guarente is best known for his research on the role of sirtuins, a class of proteins that play a key role in regulating metabolic systems in response to stress and aging. In particular, Guarente was the first to identify SIR2 as the gene that controls aging in yeast cells. The mammalian version of SIR2, SIRT1 (and its associated proteins), has since been shown by Guarente and others to play a key role in longevity and metabolic function in mammals.
Guarente’s lab is currently focused on understanding how the human brain aging transcriptional program works and how it is regulated, to pave the way for longevity therapeutic strategies for neurodegenerative disease. His team is particularly interested in the role of sirtuins in human brain aging and neurodegeneration. They are investigating the role of sirtuin levels and also sirtuin polymorphisms in regulating human brain aging rates and neurodegenerative disease risk, as well as looking broadly using unbiased genome-wide strategies.
Guarente is the Novartis Professor of Biology at MIT. He holds a B.S. from MIT and a Ph.D. from Harvard.
Title: Founder and Chief Scientist at Elysium
Lloyd A. Demetrius is a mathematician and theoretical biologist at the Max Planck Institute for Molecular Genetics at Berlin, Germany, and the Department of Organismic and Evolutionary biology, Harvard University. He is best known for the discovery of the concept, evolutionary entropy, a statistical parameter that characterizes Darwinian fitness in models of evolutionary processes at various levels of biological organization - molecular, organismic and cultural. Evolutionary entropy, an analogue of the Gibbs entropy in statistical physics, is the cornerstone of directionality theory, an analytical study of evolution by variation and selection. The theory has applications to: a) the development of aging and the evolution of longevity; b) the origin and progression of age related diseases such as cancer, and neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease; c) the evolution of cooperation and the spread of inequality.
Title: Mathematician & Theoretical Biologist
Michael is a Senior Project Manager at 10X Genomics. He was a Senior Research Associate at the Cell Biology Department, Genitope. He also was a Sr. Laboratory Operations Analyst, Genomic Health for almost 5 years. He was engaged in: CLIA, CAP, ISO 15189, Pharma laboratory audits (scribe; audit room coordination; observation/deficiency response management; CAPA, NCDR, Root Cause Analysis (RCA); Laboratory Licensing (CA, RI, PA, MD, FL application and renewals). Michael was a Senior Manager, Histology Laboratory (Genomic Health) during 2 years. He was engaged in: Management of Histology Department (45 FTE); 16 FTE hired to expand Histology Department; Management of 4 supervisors/managers (Hiring, performance review, etc.); Planning/execution of laboratory move (Facilities, Architect, IT, EH&S, Histology staff, Clinical Lab Quality)
Title: Associate Director, Program Management at 10x Genomics
CEO and Co-Founder of SENS Research Foundation, Mr. Kope received his J.D. from the University of Michigan in 1990. He has served as the University of Michigan’s Intellectual Property Counsel; as Director of Corporate Development for Aviron, and for MedImmune, Inc.; and as CEO and officer of a number of start-ups in the biotechnology space. He specializes in business development and consulting, and is widely experienced with biotechnology organizations. Mike has negotiated a broad range of business acquisition and partnership agreements, designed strategies for technology protection and promotion in many fields of research, and facilitated a number of successful startups.
Title: CEO Corporate AffairsCEO Corporate Affairs at Underdog Pharmaceuticals & Corporate Development at Aridis Pharmaceuticals
Ned co-founded UNITY in 2011, largely because he thought it was “simply the coolest biology he had ever seen.” Before UNITY, Ned co-founded four other biotechnology companies that together raised over $1.5 billion in financing and today employ over 400 scientists, engineers, and business people. Ned builds companies because he sees company creation as a means to create technologies that change the world. Ned is a co-founder of Syrrx (acquired by Takeda), Achaogen (AKAO), Kythera Biopharmaceuticals (KYTH, acquired by Allergan), and Sapphire Energy. Ned holds pending and issued patents in fields such as nanovolume crystallography, antibiotic resistance, aesthetic medicine, and cellular senescence. He has served on the board of directors of Kythera Biopharmaceuticals, Sapphire Energy, and the Buck Institute for Research on Aging and is a member of the board of trustees of the University of California Foundation. Ned was named one of the Top 100 innovators in the world under 35 by the MIT Technology Review. He holds a Ph.D. from the University of California, Berkeley in Molecular and Cellular Biology and an A.B. in Biology from Harvard University.
Title: Co-founder and DirectorCo-founder and Director at UNITY Biotechnology
Rafael de Cabo
After receiving his B.S. and M.S. from the University of Cordoba, Spain, Dr. de Cabo earned his Ph.D. in 2000 from the Department of Foods and Nutrition at Purdue University. Upon completion of his graduate education, he received a postdoctoral position in the Laboratory of Neurosciences at the National Institute on Aging in Baltimore, Maryland. In 2004, he was appointed as a tenure track investigator in the Laboratory of Experimental Gerontology, where he now heads the Aging, Metabolism, and Nutrition Unit (AMNU). The AMNU applies both physiological and tissue-specific molecular approaches to investigate effects of nutritional interventions on basic mechanisms of aging and age-related diseases. Research within his unit strives to identify protective mechanisms invoked by caloric restriction and to evaluate the consequences of dietary interventions on lifespan, pathology, and behavioral function. The AMNU balances the exploration of in vivo rodent, as well as in vitro, paradigms of caloric restriction. Dr. de Cabo is an active member of the Board of the American Aging Association.
AMNU applies whole body physiological and tissue-specific molecular approaches to investigate effects of nutritional interventions on basic mechanisms of aging and age-related diseases. Caloric restriction (CR), without malnutrition, is widely known to extend lifespan and retard a wide variety of aging processes in several short-lived species and is the primary paradigm employed by AMNU scientists. Research within this unit uses both rodent models of CR as well as an in vitro model for CR. CR affects metabolic regulation to induce an overall phenotypic change leading to a decrease in cellular proliferation and growth rates.
Title: Senior Investigator at National Institute on Aging
Richard W. Barker was educated at Exeter College, Oxford, where he received a Bachelor's degree in Chemistry. Following completion of his degree, he researched biological applications of magnetic resonance techniques in pursuit of an Oxford DPhil and in post-doctoral studies in Munich, Germany and Leeds, England.
At Chiron, a multinational biotechnology firm that was acquired by Novartis in 1996, he headed the diagnostics business, which brought the latest immunodiagnostics to market. He subsequently served as chairman and chief executive of Molecular Staging, whose genome amplification technology enables gene sequencing on rare DNA samples.
With colleagues in Oxford and UCL, he has formed CASMI to develop, test and promote new models of medical innovation, including adaptive licensing, cell therapy regulation and a combination of therapeutic and diagnostic products to focus treatments on the patients most likely to benefit.
He chairs the South London Academic Health Science Network, which aims to improve the quality and consistency of care in that part of the National Health Service (NHS), and to facilitate innovations emerging from academic and industrial research into NHS application. He chairs the charity International Health Partners that brings donated medicines to developing countries, crisis situations and refugee camps.
Title: Chair at South London Academic Health Science Network
Robert Douglas Young is a gerontology consultant and researcher best known for validating supercentenarian cases and debunking longevity claims. He is the current Senior Consultant for Gerontology for Guinness World Records (since 2005) and the Co-Director for the Gerontology Research Group (since 2015). Young has worked on several books, including Guinness World Records editions 2018, 2017, 2016, 2015, 2014, 2013, 2012, 2011, 2010, 2009, 2008, 2007, 2005 and 1997, World Almanac 2004, The Wisdom of the World's Oldest People (2005), by Jerry Friedman (whose photographic exhibits of supercentenarians were presented at the United Nations in July 2006), and Living in Three Centuries (2006), by Mark Story. Young graduated summa cum laude from Georgia State University in 2006, with a Bachelor of History degree and an Undergraduate Certificate in Gerontology. In August 2008, Young obtained a Master of Arts in Gerontology degree from Georgia State University. Young obtained a second Masters in History at GSU in 2011, with a concentration in World History endorsement. Young's interdisciplinary approach, combining gerontology and history, led to such works as the history of extreme longevity tracking, the history of longevity mythology, and the like. Robert has, since 1999, maintained lists of the world's oldest people for the Gerontology Research Group (becoming the main person in charge of the data since May 2002), and has also worked with the Max Planck Institute for Demographic Research, the New England Centenarian Study and the Social Security Administration to establish global databases on the world's oldest people. Jean-Marie Robine of France, validator of the Jeanne Calment case, worked with INSERM to establish the International Database on Longevity in 2005. Young is now a listed contributor as of 2010.
Title: Senior Consultant for Gerontology at Guinness World Records, Quality Assurance at Sterling Deaerator Company & Senior Claims Researcher at Gerontology Research Group
Dr. Horvath is an aging researcher and bioinformatician whose research lies at the intersection of epidemiology, chronic diseases, epigenetics, genetics, and systems biology. He developed systems biologic approaches such as weighted gene co-expression network analysis. He works on all aspects of biomarker development with a particular focus on genomic biomarkers of aging.
He developed a highly accurate multi-tissue biomarker of aging known as the epigenetic clock. Salient features of the epigenetic clock include its high accuracy and its applicability to a broad spectrum of tissues and cell types. He develops and applies methods for analyzing and integrating gene expression-, DNA methylation-, microRNA, genetic marker-, and complex phenotype data. His lab members apply and develop data mining methods to study a broad spectrum of diseases, e.g. aging research, cancer, cardiovascular disease, HIV, Huntington's disease, neurodegenerative diseases.
Title: Founder at Ideations, Founder at SilkRoad Cooperation, Advisor To The Board at Perusal Global Solutions & Partner at Burj Financial
Thomas Rando is Professor of Neurology and Neurological Sciences at Stanford where he is the Director of the Glenn Laboratories for the Biology of Aging. He is also Chief of Neurology and Director of the Rehabilitation Research & Development Center of Excellence at the Veterans Affairs Palo Alto Health Care System. He is a founding director of the Muscular Dystrophy Association clinic at the Stanford Medical Center. Research in the Rando laboratory focuses on tissue-specific stem cells in aging and disease, and on pathogenetic mechanisms and gene therapy for muscular dystrophies. His research on aging has demonstrated that it is possible to identify biochemical stimuli that can induce stem cells in old tissues to repair injuries as effectively as in young tissues, and this work has broad implications for the fields of regenerative medicine and stem cell transplantation.
He is a member of several professional societies, including the American Neurological Association. He is a former Paul Beeson Physician Faculty Scholar in Aging awarded by the American Federation for Aging Research and a former Ellison Medical Foundation Senior Scholar in Aging. In 2005, he received an NIH Director’s Pioneer Award for his groundbreaking research in stem cell biology. He received a BA from Harvard College, MD from Harvard Medical School and PhD in Cell and Developmental Biology from Harvard University.
Title: Professor of Neurology and Molecular, Cell & Developmental Biology at University of California, Los Angeles
Dr. Vadim Gladyshev, Professor of Medicine and Director of Redox Medicine at Brigham and Women’s Hospital, Harvard Medical School, in Boston, Massachusetts. He is an expert in aging and redox biology and is known for his characterization of the human selenoproteome. His research laboratory focuses on comparative genomics, selenoproteins, redox biology, and, naturally, aging and lifespan control.
Dr. Gladyshev graduated from Moscow State University, in Moscow, Russia; his postdoctoral studies in the 1990s took place at the National Heart, Lung, and Blood Institute, and the National Cancer Institute, in Bethesda, Maryland. Even when he was young, he was very much interested in chemistry and experimental science: he twice won the regional Olympiad in chemistry and graduated from high school with a gold medal. He also graduated with the highest honors from Moscow State University. This enviable track record is even more impressive considering that Dr. Gladyshev completed music school and high school at the same time and became a chess player equivalent to national master during his college years.
Title: Professor at BWH and HMS
Anthony Atala, M.D., is the W.H. Boyce professor and director of the Wake Forest Institute for Regenerative Medicine, and chair of the Department of Urology at Wake Forest School of Medicine in North Carolina. Regenerative medicine is "a practice that aims to refurbish diseased or damaged tissue using the body's own healthy cells".
Dr. Atala is one of the most influential names in the field of regenerative medicine and biotechnology. His research focuses on growing human cells and tissues for use in transplants, and given the constant dire need for organ donors worldwide, his work is poised to improve—and save—the lives of millions. He and his team have already successfully engineered and transplanted bladders into living patients, and as he’s told us himself, more types of tissue have been engineered and tested in models; hopefully, they will one day be usable in patients as well.
Dr. Atala’s groundbreaking work has earned him countless awards, prizes, and nominations in well-known magazines, such as Scientific American, Time Magazine, the Huffington Post, and many others; he has also served on the boards and committees of several organizations, such as the National Institutes of Health, the National Cancer Institute, and SENS Research Foundation. In 2011, he was elected to the Institute of Medicine of the National Academy of Sciences. He was named by Scientific American as a Medical Treatments Leader of the Year for his contributions to the fields of cell, tissue, and organ regeneration. Dr. Atala's work was listed as one of Time Magazine's top ten medical breakthroughs of the year, and as Discover Magazine's top science story of the year in the field of medicine in 2007. He serves on the editorial board of the scientific journal Rejuvenation Research and on the national board of advisors for High Point University.
Title: Director, Wake Forest Institute for Regenerative Medicine and Chair, Dept of Urology
J. Craig Venter, PhD, is regarded as one of the leading scientists of the 21st century for his numerous invaluable contributions to genomic research. Dr. Venter is Founder, Chairman, and CEO of the J. Craig Venter Institute (JCVI), a not-for-profit, research organization with approximately 200 scientists and staff dedicated to human, microbial, plant, synthetic and environmental genomic research, and the exploration of social and ethical issues in genomics.
Dr. Venter also is a co-founder of Synthetic Genomics, Inc. (SGI) and Human Longevity, Inc. (HLI). SGI is a privately held company developing products and solutions including sustainable bio-fuels, vaccines, biotherapeutics and transplantable organs. HLI is a genomic-based, health intelligence company empowering proactive healthcare.
Dr. Venter is one of the most frequently cited scientists, and the author of more than 280 research articles. He is also the recipient of numerous honorary degrees, public honors, and scientific awards, including the 2008 United States National Medal of Science, the 2002 Gairdner Foundation International Award, the 2001 Paul Ehrlich and Ludwig Darmstaedter Prize and the King Faisal International Award for Science. Dr. Venter is a member of numerous prestigious scientific organizations including the National Academy of Sciences, the American Academy of Arts and Sciences, and the American Society for Microbiology.
Title: President, Chairman at J. Craig Venter Institute
George leads Synthetic Biology at the Wyss Institute, where he oversees the directed evolution of molecules, polymers, and whole genomes to create new tools with applications in regenerative medicine and bio-production of chemicals. Among his recent work at the Wyss is development of a technology for synthesizing whole genes, and engineering whole genomes, far faster, more accurate, and less costly than current methods. George is widely recognized for his innovative contributions to genomic science and his many pioneering contributions to chemistry and biomedicine. In 1984, he developed the first direct genomic sequencing method, which resulted in the first genome sequence (the human pathogen, H. pylori). He helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. George invented the broadly applied concepts of molecular multiplexing and tags, homologous recombination methods, and array DNA synthesizers. His many innovations have been the basis for a number of companies including Editas (Gene therapy); Gen9bio (Synthetic DNA); and Veritas Genetics (full human genome sequencing).
George is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT). He is Director of the U.S. Department of Energy Technology Center and Director of the National Institutes of Health Center of Excellence in Genomic Science. He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute and election to the National Academy of Sciences and Engineering.
Title: Co-Founder at Colossal Biosciences, Professor at Harvard Medical School & Co-Founder at digiD8
Dr. Fossel is the driving force behind Telocyte and has been the leader in proposing the use of telomerase to treat human disease for the past two decades. Born in 1950, Michael Fossel grew up in New York, and lived in London, Palo Alto, San Francisco, Portland, and Denver. He graduated cum laude from Phillips Exeter Academy, received a joint BA and MA in psychology in four years from Wesleyan University in Connecticut, and, after completing a PhD in neurobiology at Stanford University in 1978, went on to finish his MD at Stanford Medical School in two and a half years. Dr. Fossel was a Clinical Professor of Medicine at Michigan State University for almost three decades and taught the Biology of Aging at Grand Valley State University. He has been a member of numerous scientific organizations including the American Association for the Advancement of Science, the American Aging Association (he was their executive director and served on their board of directors), the American Gerontological Society, the American Society on Aging, the American Geriatrics Society, and the Alzheimer’s Association ISTAART, among others. He was founding editor of Rejuvenation Research. In 1996, Dr. Fossel published Reversing Human Aging, the first book to ever describe the medical aspects of extending human telomeres and the potential for curing age-related disease. Still the only medical textbook on the clinical potential of telomerase, it includes in depth discussions of Alzheimer’s disease, the progerias, atherosclerosis, osteoporosis, immune senescence, skin aging, and cancer, as well as the potential for fundamentally new therapies for these diseases using telomerase therapy. His most recent book, The Telomerase Revolution (BenBella Books, 2015), discusses aging, clinical disease, and the prospective FDA clinical trials of telomerase therapy.
Title: President at Telocyte
Michael Rae is the co-author of Ending Aging and is one of Dr Aubrey de Grey's research assistants at SENS.
Michael was also a member of the Society's Board for several years. Michael is heavily steeped in the science of CR, as well as the broader field of aging research. He is also Science Writer at SENS Research Foundation, a biomedical charity developing a new class of therapies to remove and repair the cellular and molecular damage of aging. To further the Society's mission of supporting the science and practice of human CR, Michael will be coordinating with researchers to help promote, initiate, and advance this new science.
Michael Rae is the author of five scientific articles and commentaries in peer-reviewed scientific journals. Much of his work has been devoted to elucidating the SENS platform for longevity biomedicine for a popular audience. His undergraduate minor was in biology. He is a long-time member and one-time Board Member of the Calorie Restriction Society, a main contributor to the Society’s “How-to Guide”, and was core scientific investigator with the CR Society Cohort Study.
Title: Science Writer at SENS Research Foundation
Ray Kurzweil is an American inventor and futurist. He is involved in fields such as optical character recognition (OCR), text-to-speech synthesis, speech recognition technology, and electronic keyboard instruments. He has written books on health, artificial intelligence (AI), transhumanism, the technological singularity, and futurism. Kurzweil is a public advocate for the futurist and transhumanist movements, and gives public talks to share his optimistic outlook on life extension technologies and the future of nanotechnology, robotics, and biotechnology. Kurzweil received the 1999 National Medal of Technology and Innovation, the United States' highest honor in technology, from President Clinton in a White House ceremony. He was the recipient of the $500,000 Lemelson-MIT Prize for 2001, the world's largest for innovation. And in 2002 he was inducted into the National Inventors Hall of Fame, established by the U.S. Patent Office. He has received 21 honorary doctorates, and honors from three U.S. presidents. The Public Broadcasting Service (PBS) included Kurzweil as one of 16 "revolutionaries who made America" along with other inventors of the past two centuries. Inc. magazine ranked him #8 among the "most fascinating" entrepreneurs in the United States and called him "Edison's rightful heir".
Title: CEO at Kurzweil Technologies Inc
Richard Faragher is Professor of Biological Gerontology at the University of Brighton and past Chair of the British Society for Research on Ageing, the International Association of Biomedical Gerontology and the American Aging Association. His primary research interest is the relationship between cellular senescence and organismal ageing. In 2002 his work on the accelerated ageing disease Werner’s syndrome led to the award of the Royal Pharmaceutical Society Conference Science Medal for outstanding scientific achievement. In 2005 he became the first ever scientist to receive a Help the Aged award for my championship of older people and the use of research for their benefit.
In 2010, he became the first ever British recipient of the Paul F Glenn Award for research into the biological mechanisms of the ageing process. He is a visiting Professor at the Moscow Institute of Physics and Technology and a Trustee of the Biogerontology Research Foundation. He has served as a member of the Research Advisory Council of the Charity Research into Ageing and on strategy and funding panels for the BBSRC, the US National Institutes on Ageing and the European Union. From 2005-2008 he was Co-director of the BBSRC-EPSRC SPARC programme, a research network designed to build national capacity to conduct inter-disciplinary ageing research. In 2015 he became the first British citizen to be elected to the Board of Directors of the American Federation for Aging Research, the leading US non-profit organization supporting and advancing healthy aging through biomedical research. In 2016 he was presented with the highest award for services to gerontology in the United Kingdom, the Lord Cohen of Birkenhead Medal and became a Fellow of the American Aging Association.
Title: Professor of Biological Gerontology at the University of Brighton
Antonio is the senior editor for biomedicine for MIT Technology Review. He looks for stories about how technology is changing medicine and biomedical research.
Before joining MIT Technology Review in July 2011, he lived in São Paulo, Brazil, where he wrote about science, technology, and politics in Latin America for Science and other publications.
From 2000 to 2009, he was the science reporter at the Wall Street Journal and later a foreign correspondent.
Title: Biomedicine Editor at MIT Technology Review
Keith Comito is a mathematician, computer programmer and biotechnology enthusiast based in New York City. In addition to developing high-profile mobile applications such as HBO NOW and Disney Plus, he explores the intersection of technology and biology at the Brooklyn community lab Genspace, and is a passionate supporter of research aimed at extending healthy human lifespan.
Keith is also a practitioner of several martial arts, writer of music, and host of a retro video game–themed YouTube channel.
Specialties: Swift, Objective-C iPhone/iPad Development, Object Orientated Development, Crowdfunding, Video Editing, Augmented Reality
Title: Lead Software Engineer - Technology Lead, Advanced Research at Disney Streaming Services & Co-Founder and President at Lifespan Extension Advocacy Foundation / Lifespan.io
Paul Irving is chairman of the Milken Institute Center for the Future of Aging and distinguished scholar in residence at the University of Southern California Davis School of Gerontology. Irving also serves as chairman of Encore.org, a director of East West Bancorp, Inc. and Pharos Capital BDC, Inc., and an advisory board member at USC, Stanford University, the Global Coalition on Aging, and WorkingNation.
He previously served as the Milken Institute’s president, an advanced leadership fellow at Harvard University, and chairman and CEO of Manatt, Phelps & Phillips, a law and consulting firm. Author of “The Upside of Aging: How Long Life Is Changing the World of Health, Work, Innovation, Policy, and Purpose,” a Wall Street Journal expert panelist and contributor to PBS Next Avenue and Forbes, Irving is involved in initiatives at the National Academy of Medicine and the Bipartisan Policy Center, and was a participant in the 2015 White House Conference on Aging. He was honored with the Janet L. Witkin Humanitarian Award by Affordable Living for the Aging, the Life Journey Inspiration Award by Stanford’s Distinguished Careers Institute, and the Board of Governors Award by Loyola Law School, Los Angeles. PBS Next Avenue named Irving an “Influencer” for his work in aging and longevity.
Title: Senior Fellow at Milken Institute, Distinguished Scholar in Residence at USC Davis School of Gerontology & Director at East West Bancorp, Inc.
Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 500 articles on the topic as well as attending various medical industry conferences.
In 2019 he was listed in the top 100 journalists covering biomedicine and longevity research in the industry report – Top-100 Journalists covering advanced biomedicine and longevity created by the Aging Analytics Agency. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, and, Keep me Prime, and New Economy Magazine.
Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
In 2015 he led the Major Mouse Testing Program (MMTP) for the International Longevity Alliance and in 2016 helped the team of the SENS Research Foundation to reach their goal for the OncoSENS campaign for cancer research.
Title: Editor in Chief at Lifespan.io & Project CoordinatorProject Coordinator at Major Mouse Testing Program
For over 30 years his passion has been helping people to breakthrough and take their lives to another level - no matter how successful they already are - in the areas that matter most: their business, personal finance, intimate relationships, families, careers and health.
He has been honored to help over 50 million people from more than 100 countries transform their lives and their businesses through his live events, books, audio programs, health products and personal coaching. He has been fortunate enough to work with everyone from presidents of countries, to some of the true legends of entertainment, sports and the business world. But his work is not limited to Fortune 500 CEOs and athletes. He have a special passion for small business owners, parents and students.
Being the Chairman of 7 privately-held companies and 5 holding companies in diverse industries keeps him pretty busy. Many of our companies have become brands that are leaders in their category - from the award winning Namale Resort & Spa in the Fiji Islands, to Twinlab and Metabolife in the sports nutrition field, to the Anthony Robbins brand in personal & professional improvement.
Title: Chairman at Robbins Research International
Arthur D. Levinson (born March 31, 1950) is an American businessman and is the current chairman of Apple Inc. (2011–present) and CEO of Calico (an Alphabet Inc. venture). He is the former chief executive officer (1995–2009) and chairman (1999–2014) of Genentech.
In addition to serving on the board of Apple Inc. (2000–present), Levinson serves on the board of directors of the Broad Institute (affiliated with MIT and Harvard). Previously, Levinson had served on the board of directors at F. Hoffmann-La Roche (2010–2014), NGM Biopharmaceuticals (2009–2014), and Amyris Biotechnologies (2009–2014). He currently serves on the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer Center, the Industrial Advisory Board of the California Institute for Quantitative Biosciences (QB3), the advisory council for the Princeton University Department of Molecular Biology and the advisory council for the Lewis-Sigler Institute for Integrative Genomics.
Title: CEO of Calico
James Peyer is the Chief Executive Officer and Co-Founder of Cambrian Biopharma. James was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. He led investments in Cleara Biotech, Aeovian Pharmaceuticals, and Samsara Therapeutics, and served on theBoard and/or in executive roles for all three companies. James has led companies that have raised over $100M. He serves on the board of Sensei Biotherapeutics, Vineyard Therapeutics, and several more stealth-mode companies. Prior to Apollo, James was a consultant at the New York office of McKinsey & Company, serving major pharmaceutical clients. He earned his PhD in stem cell biology at University of Texas Southwestern Medical Center as a National Science Foundation Fellow and received his B.A. with special honors from the University of Chicago.
Title: Founder & CEO at Cambrian Biopharma
Keith R. Leonard, Jr. is our co-founder and has served as our President and Chief Executive Officer and as a member of our Board since August 2005.
Title: Chair of the Board of Directors at UNITY Biotechnology & Chair of the Board of Directors at LA Opera
Dr. Bill Andrews is the President and CEO of Sierra Sciences. As a scientist, athlete and executive, he continually pushes the envelope and challenges convention. He has been featured in Popular Science, The Today Show and numerous documentaries on the topic of life extension including, most recently, the movie The Immortalists in which he co-stars with Aubrey de Grey. In his 36 year biotech career, he has focused the last 24 years on finding ways to extend the human lifespan and healthspan through telomere maintenance.
As one of the principal discoverers of both the RNA and protein components of human telomerase, Dr. Andrews was awarded 2nd place as “National Inventor of the Year” in 1997. He earned his Ph.D. in Molecular and Population Genetics at the University of Georgia in 1981. He has served as Senior Scientist at Armos Corporation and Codon Corporation, Director of Molecular Biology at Berlex Biosciences and at Geron Corporation, and Director of Technology Development at EOS Biosciences.
He is also a named inventor on over 50 US issued patents on telomerase and author of numerous scientific research studies published in peer reviewed scientific journals.
Bill is also an avid ultra-marathon runner. At the age of 65, he regularly competes in 100k and 100+ mile runs often finishing at the top of his age group. These grueling races have taken him all over the world to race in some of the most extreme environments, from Death Valley to the Himalayas. His running is presently featured in the movie The High.
Title: President & CEO at Sierra Sciences
Bryan Johnson is founder of Kernel, OS Fund and Braintree.In 2016, he founded Kernel, investing $100M to build advanced neural interfaces to treat disease and dysfunction, illuminate the mechanisms of intelligence, and extend cognition. Kernel is on a mission to dramatically increase our quality of life as healthy lifespans extend. He believes that the future of humanity will be defined by the combination of human and artificial intelligence (HI +AI).
In 2014, Bryan invested $100M to start OS Fund which invests in entrepreneurs commercializing breakthrough discoveries in genomics, synthetic biology, artificial intelligence, precision automation, and new materials development.
In 2007, Bryan founded Braintree (acquired Venmo) which he sold to PayPal in 2013 for $800M.
Bryan is an outdoor-adventure enthusiast, pilot, and author of a children's book, Code 7.
Title: Founder at Kernel & Founder at OS Fund
David Gobel, one of the pillars of our longevity science and advocacy community, co-founded the Methuselah Foundation with Aubrey de Grey way back when, and continues to run that organization today. Over the years he has supervised a diverse set of grants, projects, and successful investments in tissue engineering and aging research, including the first SENS rejuvenation research programs, prior to the launch of the SENS Research Foundation. With the recent influx of capital to new companies seeking to produce therapies that target mechanisms of aging, investment at the Methuselah Foundation has expanded to become the Methuselah Fund, a hybrid for-profit/non-profit vehicle that will continue the work of accelerating progress towards meaningful rejuvenation therapies.
Title: Co-founder at Methuselah Foundation
John D. Furber is a scientist and entrepreneur who has been studying the biology of aging, development, and regeneration for more than 25 years. During this time, he has been piecing together a Network Model of the Systems Biology of Human Aging, which can be seen at https://legendarypharma.com/chartbg.html.He is a frequent contributor at meetings in the fields of aging, mitochondria, autophagy, and oxidative stress. These include Gordon Research Conferences, Cold Spring Harbor Conferences, Ellison Colloquia, Harvard/Glenn Symposia, American Aging Association, Gerontological Society of America, International Society on Aging and Disease, SENS Conferences, Oxygen Club of California World Congresses, and the Bay Area Aging Meetings. From 2000-2011, he served on the Board of Directors of the American Aging Association and was twice elected as VP. He earned a Bachelor degree in Physics and Mathematics from the University of California at Santa Cruz in 1975, and a Master of Science degree in Biological Sciences (Developmental and Molecular Biology) from the University of California at Irvine in 1990, where he advanced to PhD Candidacy. Between degrees, he served the United States Congress as a Technology Policy Analyst in the Congressional Office of Technology Assessment. Currently, he is running Legendary Pharmaceuticals, small pharmaceutical research company that is engaged in the discovery of pharmaceutical drugs and gene therapies able to repair and reverse accumulating molecular damage to subcellular mitochondria, lysosomes, nuclei, and extracellular proteins in order to prevent and treat serious, late-onset diseases commonly associated with aging. Legendary Pharmaceuticals is a privately-held small business. He is a frequent contributor at meetings in the fields of aging, mitochondria, autophagy, and oxidative stress. He served on the Board of Directors of the American Aging Association from 2000 to 2011, and was Vice President in 2008-2009.
Title: CEO at Legendary Pharmaceuticals
Joshua has co-invented and secured over a dozen patents in the areas of multi-tissue regeneration and gene expression modulation in collaboration with co-inventors at his company, Stanford University, and the University of California Berkeley. McClure leads a team of some of the world's top scientists and clinicians in the field of tissue regeneration, using computational systems medicine to personalize therapies to fight chronic disease and optimize human performance.
A graduate of the USAF Academy, McClure has been a leader of tech companies for over 15 years and comes to industry with a background in top-secret USAF projects. He has invented multiple category-first companies, revolutionary new technologies and now devotes his time to biotechnologies with the capacity to reverse age-related degeneration and optimize human longevity. MaxWell is working with Mayo Clinic, The American Red Cross and other large companies to bring these technologies to humans.
Title: CEO at Maxwell Biosciences
Stephen Johnston MBA is a co-founder of Aging2.0 a global innovation platform for aging and senior care, founder of Fordcastle, an innovation consultancy and a member of the Future Agenda, the world’s largest open foresight initiative. Stephen serves on the board of Music and Memory a New York 501c3 nonprofit focused on improving the quality of life for older people, He is co-author of Growth Champions (Wiley, 2012), a book about sustainable corporate growth. He has an MA in Economics from Cambridge University and an MBA from Harvard Business School where he was a Fulbright Scholar.
Title: Founder at The Collective
Zoltan Istvan, an American-Hungarian, began a solo, multi-year sailing journey around the world at the age of 21. His main cargo was 500 handpicked books, mostly classics. He's explored over 100 countries—many as a journalist for the National Geographic Channel—writing, filming, and appearing in dozens of television stories, articles, and webcasts. His work has also been featured by The New York Times, Outside, Wired UK, Slate, Vice, San Francisco Chronicle, BBC Radio, CNN, CBS, RT, Fox News, the Travel Channel, and in much other media. In addition to his award-winning coverage of the war in Kashmir, he gained worldwide attention for pioneering and popularizing the extreme sport of volcano boarding. Zoltan later became a director for the international conservation group WildAid, leading armed patrol units to stop the billion-dollar illegal wildlife trade in Southeast Asia. Back in America, he started various successful businesses, from real estate development to filmmaking to viticulture, joining them under ZI Ventures. He is a philosophy and religious studies graduate of Columbia University and resides in San Francisco with his daughters and physician wife. Zoltan recently published "The Transhumanist Wager," an award-winning fictional thriller describing philosopher Jethro Knights and his unwavering quest for immortality via science and technology. It was a Top 5 Amazon book. Zoltan writes futurist and transhumanist-themed blogs for The Huffington Post, Psychology Today, and Vice's Motherboard. Zoltan is also founder of the Transhumanist Party and ran a successful and widely viewed 2016 US presidential campaign. He is one of the most visible and popular futurists in the world. In 2018, he was an endorsed Libertarian candidate for California Governor.
Title: Public Figure in Transhumanism
Bill Maris (born 1975, full name William J Maris) is an American entrepreneur and venture capitalist focused on technology and the life sciences. He is the founder and first CEO of Google Ventures (GV). He is the creator of Google's Calico project, a company focused on the genetic basis of aging. He is the founder of early web hosting pioneer Burlee.com, now part of Web.com, and the founder of Section 32, a California-based venture fund focused on frontier technology.In the mid 2000s, Maris partnered with entrepreneur David Green to transfer a novel hydrophobic acrylic lens to Aurolab to cure cataract blindness in the developing world, where it has been used in more than 30 million patients. Maris founded GV, formerly Google Ventures, in 2008 as the venture capital investment arm of Google Inc. He was responsible for the fund's strategy and management, and oversaw $3.0 billion in investments in technology and the life sciences. Maris was one of the first to cite the troubles with Theranos, the troubled Silicon Valley blood testing company. Maris founded Calico, a multibillion-dollar company whose mission is to understand and influence the genetic basis of aging. Google funded the company after Maris pitched the board of directors. In a 2015 interview, Maris stated that health care breakthroughs can significantly improve the quality and duration of human lifespan across the globe, and that he is looking to invest in promising biotechnology companies. Maris was also the Vice President of Special Projects at Google, where he was heavily involved in Google X, Verily. Maris left Google Ventures on August 12, 2016, declaring "mission accomplished." In 2017 Maris founded Section 32, a California-based venture fund with approximately $400 million under management.
Title: Director of Projects at de Havilland Aircraft Museum
Kevin Perrott is Founder and CEO of OpenCures, Treasurer of SENS Research Foundation, co-founder of Oisin Biotechnologies.
After twenty years of growing and managing a successful retail business, Kevin became a cancer survivor and shifted direction to academics to develop methods of curing cancer and other age-related diseases. He graduated from the University of Alberta in 2006 at the age of 43 with a double major in Biology and Chemistry. He then entered the Ph.D. program and after completing two years studying the role of mitochondria in the process of aging in the nematode C. elegans, he shifted focus to the importance of the phenomenon of mammalian cellular senescence and its role in degenerative disease.
Kevin continues to support the advance of aging research as the VP of the American Aging Association, and through his research at the Buck Institute for Research on Aging in the lab of Judith Campisi sponsored by SENS Foundation to mitigate the negative effects of senescent cells.
Title: Adjunct Professor at University of Alberta
Michael D. West is a gerontologist, and a pioneer in stem cells, cellular aging and telomerase. He is the founder and CEO of AgeX Therapeutics, a startup focused on the field of interventional gerontology, and Co-CEO of its parent company, BioTime, Inc. of Alameda, California (San Francisco Bay Area), a biotechnology company regarded as a leader in the field of regenerative medicine with a focus on cell therapy.Prior to joining BioTime, West was Chairman of the Board, Chief Scientific Officer and CEO of Advanced Cell Technology (ACT), another biotechnology company focused on stem cell research. ACT later changed its name to Ocata Therapeutics, and was acquired by Japanese pharmaceutical company Astellas Pharma for US$379M or $8.50 per share in February 2016. Prior that, West was founder, director, and Chief Scientific officer of Geron, for which he secured venture capital investment from Kleiner Perkins Caufield & Byers, Venrock and Domain Associates. At Geron, West initiated and managed programs in telomere biology relating to aging, cancer and human embryonic stem cell technology. West organized the first collaborative effort to isolate human pluripotent (embryonic) stem cells for the purpose of manufacturing products in regenerative medicine in collaboration with James Thomson at the University of Wisconsin at Madison, John Gearhart at Johns Hopkins School of Medicine, and Roger Pedersen at the University of California, San Francisco. West and colleagues at Geron cloned the RNA component of telomerase and collaborated with Thomas Cech (winner of 1989 Nobel Prize in Chemistry), with whom they cloned the catalytic component of the enzyme telomerase, and sponsored collaborative research in the laboratory of Carol Greider, then at Cold Spring Harbor Laboratory.
Title: CEO at AgeX Therapeutics
David Geoffrey Nigel Filkin, Baron Filkin CBE (born 1 July 1944) is a British Labour politician. Filkin was educated at King Edward VI Five Ways School, Birmingham, and Clare College, Cambridge, where he read history. His early career was as a Director of Housing and then Chief Executive in Local Government. He was Chief Executive of the Association of District Councils, representing local authorities to government, promoting the foundation of the Local Government Association and creating Best Value, the policy for sourcing in local government. Later he was a policy analyst and writer, contributing to the development of Labour’s policies for local and regional government. In 2000 he led the Prime Minister's Review of local government and subsequently was a government minister for four years. He founded the Public Services Research Group which published Public Matters, a critical review of Labour’s public service reforms and in 2008 he founded and chaired the charity, 2020 Public Services Trust. Its Commission into Public Services in 2020 reported in 2010. He led the report, Commissioning for Outcomes, proposing and explaining the policy of paying for results. He was made an Honorary Fellow of the Chartered Institute for Purchasing and Supply. He founded the Parliament Choir in 2000, chaired the Committee on Statutory Instruments from 2005–10 and proposed and then chaired the Lords Select Committee on Public Services and Demographic Change. Its report, Ready for Ageing? was published in March 2013. Geoffrey Filkin was Chair of the House of Lords Select Committee on Public Service and Democratic Change which published a report on "Ready for Ageing?".
Title: Chair at Centre for Ageing Better
George is an innovation leader specialising in health and care. His focus is on novel service propositions that empower service users, offer value to care systems and maximise the potential of digital technologies. His work includes supporting companies enter new markets in care, establishing scalable technology ecosystems and working at a system level to shape policy to promote new services.
George’s recent work has a strong international dimension, with experience covering the USA, Ireland, the Nordics and Middle East. He recently gave evidence in Ireland to the Oireachtas Joint Committee on Health on future capacity requirements and the need to accelerate the shift of care away from hospitals and residential settings to provide a better experience and improved outcomes. For 10 years he led the user group for the Continua Health Alliance, a global industry group working to promote connected personal wellness and care.
He has twice been recognised with a Continua ‘Key Contributor’ award and he is member of the European special interest group advising on regulatory reform for telemedicine.
Title: Healthy Ageing Challenge Director at UK Research and Innovation
John has worked in the City for over 30 years, providing advice on corporate affairs and communications to US, European and Japanese financial institutions.
He joined Legal & General as Group Communications Director in 2006, becoming Corporate Affairs Director following the global financial crisis. Since then, his responsibilities have variously included communications, public affairs and policy, corporate social responsibility and brand. In 2016 he left Legal & General to work in government as head of the Prime Minister’s Downing Street Policy Unit, returning to the company in September 2017.
Title: Corporate Affairs Director at Legal & General
Matthew John David Hancock (born 2 October 1978) is a British Conservative Party politician, since 2018 Secretary of State for Health and Social Care. He has been Member of Parliament (MP) for West Suffolk since 2010.
Hancock was born in Cheshire, where his family run a software business. Hancock studied PPE at Exeter College, Oxford and Economics at Christ's College, Cambridge. He was an economist at the Bank of England before becoming an economic advisor (and later Chief of Staff) to George Osborne.
Elected in 2010, he served in a number of middle-ranking ministerial positions from September 2013 under both David Cameron and Theresa May. He was promoted to the Cabinet as Secretary of State for Digital, Culture, Media and Sport in January 2018. On 9 July 2018, after the promotion of Jeremy Hunt to Foreign Secretary, Hancock was named Secretary of State for Health and Social Care. On 25 May 2019, Hancock announced his intention to stand for leadership of the Conservative Party.
Title: MP for West Suffolk at House of Commons
Prince Michael of Liechtenstein
Prince Michael of Liechtenstein has completed his trainings at the Faculty of Economics with the University of Vienna (Austria) with a Magister der Sozial- und Wirtschaftswissenschaften (M.A. in Business Administration). During his studies he took various practical training periods / work with banks and manufacturing companies in Canada, the US and Belgium (Brussels).
From 1978 to 1987 he worked for Nestlé SA in the fields of controlling, management and marketing on various markets in Europe and Africa.
In 1987 he returned to Liechtenstein where he took over the position of a Managing Director with Industrie- und Finanzkontor Ets. Vaduz, which today is a leading trust company with tradition and expertise in the long-term and trans-generational preservation of wealth, especially family wealth. Today, Prince Michael von und zu Liechtenstein is Chairman of Industrie- und Finanzkontor Ets. as well as Founder and Chairman of Geopolitical Intelligence Services AG Vaduz.
Prince Michael von und zu Liechtenstein is member of various professional organisations such as STEP. Furthermore, he is board member of the Liechtenstein Institute of Professional Trustees and Fiduciaries as well as Chairman of the European Center of Austrian Economics Foundation Vaduz.
Title: President at European Center of Austrian Economics Foundation
Damian Howard Green (born 17 January 1956) is a British politician who has been the Conservative Member of Parliament for Ashford since 1997 and was the First Secretary of State and Minister for the Cabinet Office from 11 June 2017 to 20 December 2017. Green was born in Barry, Vale of Glamorgan, South Wales and studied PPE at Balliol College, Oxford. Before entering